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ABSTRACT
The use of advanced imaging techniques has greatly improved orthopedic
research and education. Histology of bone is a method of evaluating bone morphology,
bony cells, and bone remodeling in two-dimensions, while micro-computed tomography
(microCT) is a three-dimensional analysis of bone morphology. Combined, these
methods assist in providing a comprehensive analysis of bone. In this dissertation,
these techniques were utilized to answer questions currently outstanding in veterinary
medicine: the effect of bisphosphonates on equine bone, and variation in murine tarsal
anatomy.
Bisphosphonates are drugs that reduce osteoclast-mediated bone resorption and
have recently been approved for the use in horses. Despite prolific clinical use, there
has been little evidence of their effect on bone in horses. Therefore, the goal of these
studies was to determine the impact of bisphosphonates on bone in normal, young
horses. This was accomplished by evaluating bone biopsies taken before and 60 days
after a single bisphosphonate administration. Biopsies were analyzed using microCT
and histomorphometry. We found that the bisphosphonates studied have minimal to no
effect on bone morphology and remodeling, and therefore conclude that these drugs do
not negatively impact bone, and have no effect after 60 days.
Mice are the most commonly utilized animal model for orthopedic research, and
knowledge of normal anatomy is critical to identify pathologies secondary to disease.
We found conflicting evidence regarding the tarsal anatomy in the mouse. While normal
tarsal variation exists in other species, this has not been documented in the mouse.
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Therefore, the purpose of this study was to characterize the tarsal anatomy of the
mouse. MicroCT data from muroid tarsi were collected, and representative tarsi were
evaluated by histology. Fusion of the central and tarsal bone III was present in all
laboratory mice evaluated, but was not present in the laboratory rat or wild white-footed
mouse. This fusion was confirmed via histology; however, hyaline cartilage was present,
surrounded by mature trabecular bone indicating a joint remnant despite the fused state
of the bones. We conclude that in certain laboratory mouse strains, the central and
tarsal bone III are fused into a single bone.
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CHAPTER 1.
INTRODUCTION
1.1 Review of Bone Biology
1.1.1 General Bone Anatomy
The normal human skeleton consists of 213 bones, which can be characterized
based on shape and development (Clarke, 2008). These bones articulate together to
provide a variety of functions to the body: structure and support to permit movement,
storage of calcium and phosphate to maintain mineral homeostasis, and protection of
internal organs and tissues (Weiner et al., 1999). General bone categories based on
shape include long bones (e.g., femora, radii, and metacarpals), short bones (e.g.,
carpal and tarsal bones), flat bones (e.g., calvaria and ribs), and irregular bones (e.g.,
vertebrae) (Clarke, 2008). Long bones are longer than they are wide, comprised of a
long, hollow shaft called the diaphysis, a rounded end proximal and distal to the growth
plates called the epiphyses, and the area comprised of the growth plate between the
diaphysis and epiphysis called metaphyses (Clarke, 2008). Contained within the
diaphysis is a cavity called the medullary canal (Gray, 1918). Bone marrow is located
within the bone medullary canal, and stores important hematopoietic and mesenchymal
stem cells (Gurkan and Akkus, 2008). Short bones are as long as they are wide, and
are composed of an outer cortical bone layer, with an inner trabecular bone center
(Clarke, 2008). Flat bones are broad and thin, while irregular bones do not fit into the
other categories and usually have unproportioned dimensions. However, they both
contain an inner trabecular layer between dense cortical bone layers on either side
(Gray and Goss, 1878, Rho et al., 1998).
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Bone is an organ, comprised of a hierarchical network of mineralized collagen
fibrils, carbonated apatite crystals, and water (Weiner and Wagner, 1998). There are
two types of bone based on gross morphology of the tissue: cortical and trabecular.
Cortical bone, or compact bone, is dense and solid, providing strength and structure to
bones by surrounding the medullary cavities (Clarke, 2008). Cortical bone is arranged in
osteons, which are comprised of cylindrical rings of collagen fibers called lamellae, and
contain a central canal that houses a neurovascular bundle (McGavin and Zachary,
2006). Trabecular bone, or cancellous bone, is made up of hemi-osteons and are
arranged in inter-connecting rods and plates, called trabeculae. This arrangement is
directly related to the direction of stress placed on the particular bone.
The 3 main bone cells are osteoblasts, osteocytes, and osteoclasts (Raggatt and
Partridge, 2010). Osteoblasts are derived from pluripotent mesenchymal stem cells, and
are the bone-forming cells that synthesize the organic matrix and promote
mineralization. Osteocytes are osteoblasts that become encapsulated within lacunae in
newly-formed bone. Osteocytes have long processes that extend through small tunnels
throughout the bone extracellular matrix. These small tunnels, or canaliculi, permit
communication between osteocytes, as well as the bone surface (Raggatt and
Partridge, 2010). Osteoclasts are macrophage polykaryons, formed through the
differentiation of monocyte precursor cells, that degrades bone matrix by secreting
enzymes and acid (Boyle et al., 2003).
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1.1.2 Bone Development
There are two classifications of bone development: endochondral and
intramembranous ossification. Endochondral ossification is the process where bone
replaces pre-existing cartilaginous anlagen (Olsen et al., 2000). The cartilaginous
templates are formed during embryogenesis when mesenchymal cells condense and
differentiate into chondrocytes (Erlebacher et al., 1995). After formation, chondrocytes
within the anlagen proliferate and expand, producing cartilage matrix. Centrally-located
chondrocytes mature into hypertrophic chondrocytes, creating a sequence of events
that triggers specific factors to induce angiogenesis. During angiogenesis, osteoblasts,
osteoclasts, and hematopoietic cells are brought into the location, allowing for
mineralization to occur and creating primary ossification centers (Olsen et al., 2000).
Endochondral ossification accounts for the formation of most of the skeleton, including
the appendicular and axial skeleton (Ortega et al., 2004).
Intramembranous ossification is the process by which mesenchymal cells
differentiate directly into osteoblast cells, which produce bone directly without a
cartilaginous precursor. Briefly, ossification begins with a thin layer of mesenchymal
cells. As these cells become highly vascularized, they differentiate into isolated
osteoblasts, which begin to secrete osteoid. This osteoid matrix will become mineralized
by the end of the embryonic period, forming the beginning of the osteon (Cooper et al.,
2006). Flat bones of the skull and addition of new bone along the surfaces of long
bones form through this process (Erlebacher et al., 1995).
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1.1.3 Bone Remodeling
Bones undergo normal remodeling in order to maintain structure and integrity,
repair damage in response to external and internal forces, and maintain homeostasis of
minerals within the body. Overall, there are five phases of bone remodeling: activation,
resorption, reversal, formation, and termination (Raggatt and Partridge, 2010).
However, the completion of these events may vary greatly due to pathology or
pharmacological treatments (Eriksen, 2010). During the activation phase, signals to
initiate the remodeling process are detected by osteocytes (Bonewald, 2007), which can
be due to structural damage or hormonal changes (Raggatt and Partridge, 2010), such
as changes in estrogen or PTH (Eriksen, 2010). Osteocytes play an important role in
detecting structural stresses and translating them into bone remodeling activation
signals (Aarden et al., 1994). Osteocytes secrete transforming growth factor β (TGF- β)
under normal conditions, which inhibits osteoclastogenesis and slows down overall
remodeling rates; however, when bone is under stress, osteocytes undergo apoptosis
which increases osteoclastogenesis (Aguirre et al., 2006). The resorption phase follows
activation, where osteoblasts respond to the signals produced by the osteocytes, and
recruit osteoclast precursors to the area of remodeling activity. Additionally, osteoblasts
produce a chemoattractant that recruits osteoclast precursors and receptor activators of
NF-!B ligand (RANKL), which promotes osteoclastogenesis (Li et al., 2007).
Osteoblasts also secrete matrix metalloproteinases (MMPs) that break down the lining
of the bone surface and expose adhesion sites necessary for osteoclast attachment
(Raggatt and Partridge, 2010). Osteoclasts attach themselves to the bone matrix, and
rearrange their cytoskeleton so that a dense, actin structure forms a tight seal along the
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edges of the osteoclast (Lakkakorpi et al., 1989). These edges enlarge and form a
ruffled border (Stenbeck, 2002), completing the seal, and allowing the osteoclast to
create a micro-environment within the sealed area under the osteoclast, which is critical
in bone resorption (Baron, 1989). Once attached, osteoclasts create an acidic
microenvironment by use of hydrogen pumps. Together with other enzymes, this
degrades the bone matrix beneath the osteoclast, creating a Howship’s lacuna
(Teitelbaum,

2000).

Following

resorption,

the

reversal

phase

begins,

where

mononuclear cells of undetermined lineage prepare the bone surface for bone formation
by removing collagen remnants and producing bone formation signals (Raggatt and
Partridge, 2010). Factors that initiate the formation phase from reversal phase have not
been fully identified, but include a coupling factor that promotes bone formation while
inhibiting bone resorption (Martin and Sims, 2005). Mesenchymal stem cells or
osteoblast progenitor cells are directed to the lacunae to differentiate and produce
osteoid. After deposition, hydroxyapatite is incorporated into the newly formed osteoid,
finalizing the bone formation (Raggatt and Partridge, 2010). Finally, the termination
phase begins when the resorbed bone has been replaced, which is thought to be
induced by a lack of sclerostin expression that was present during bone formation
phases (Sapir-Koren and Livshits, 2014). The resting bone surface is reestablished, and
continues in this state until the remodeling process begins again (Raggatt and
Partridge, 2010).
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1.2 Overview of Bone Diseases
1.2.1 Diseases of Bone Development
Due to the complex nature of bone formation, it should follow that any slight
disturbance in these coordinated events can result in skeletal pathologies. During
endochondral bone development, there are numerous factors that control specific
processes necessary for normal bone development. During chondrogenesis, Sox
proteins (e.g., Sox9) are critical for differentiation of mesenchymal stem cells into
chondrocytes (Akiyama et al., 2002), proliferation of chondrocytes in growth plates of
long bones (Akiyama et al., 2004), and upregulation of gene expression responsible for
producing critical components of cartilaginous matrix (Bi et al., 2001). Additionally,
fibroblast growth factor receptor (FGFR) 3 is expressed in proliferating chondrocytes
(Provot and Schipani, 2005). FGFR3 affects long bone development and specific
mutations

within

it

cause

skeletal

dysplasias

including

achondroplasia,

hypochondroplasia, and thanotophoric dysplasia, which are all forms of short-limb
dwarfism (Vajo et al., 2000, Ornitz and Marie, 2002). Bone morphogenetic proteins
(BMPs) are vital to inducing cartilage and bone formation. During development, BMP
signaling is critical during the formation of joints by stimulating cartilage formation,
localizing the expression of joint molecular markers to the appropriate location, and
causing apoptosis at the joint location to create the cavitation (Baur et al., 2000, Yi et
al., 2000). Inhibition of BMP signals can result in brachypodism (Storm et al., 1994),
where the appendicular skeleton is affected and characterized by shorter phalanges
with irregular ossification patterns (Grüneberg and Lee, 1973). These abnormalities
occur before the formation of the cartilage anlagen and, being an abnormality of the
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blastemata, result in abnormal fusions of the carpal and tarsal bones (e.g., fusion of the
navicular and tarsal bone III in the tarsus) (Grüneberg and Lee, 1973).

1.2.2 Diseases of Bone Remodeling
In order for bone to remain structurally sound and functional, there must be a
balance of bone formation and resorption, resulting in minimal to no net changes in the
amount of bone in a healthy, mature skeleton. However, this delicate balance can be
disrupted by certain pathologies which can affect both bone forming and bone resorbing
pathways. Osteoporosis is one of the most common forms of bone remodeling
disorders, where there is an overall loss in bone mass, causing bone fragility (Feng and
McDonald, 2011). Due to the broad nature of this disease, it is divided into primary and
secondary types (Panel, 2001, Marcus and Bouxsein, 2008). Primary osteoporosis is
caused by age-related events, such as decreased gonadal activity (Riggs et al., 1969),
while secondary osteoporosis is a consequence of chronic medical conditions that result
in bone loss, such as cancer, hyperparathyroidism, use of corticosteroids, renal failure
and vitamin D deficiency (Moyad, 2003, Painter et al., 2006). Age-related osteoporosis
occurs most commonly due to the lack of gonadal function (Riggs et al., 1969), where
there is a decrease in estrogen or testosterone. This leads to increased bone resorption
that exceeds normal bone formation, resulting in a net loss of bone. However,
osteoporosis does occur in both men and women, and can occur before age-related
hormonal changes (Riggs et al., 1969, Painter et al., 2006). Hypogonadism can occur in
young women and men, such as during androgen deprivation therapy for prostate
carcinoma (Mittan et al., 2002) or anorexia (Grinspoon et al., 2000). Aside from sex
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hormone changes, there are multiple factors that lead to an increase in parathyroid
hormone (PTH) levels, such as primary hyperparathyroidism (Painter et al., 2006) or a
decrease in calcium resorption in the gastrointestinal tract (Feng and McDonald, 2011),
that result in increased bone resorption rate.
Bone remodeling disease in humans, such as with osteoporosis, affects the
entire skeleton and is a systemic change in bone mass. In some animal species,
however, bone disorders exist that affect only specific bones and do not result in a net
change in the rest of the skeleton. In the horse, navicular disease is a degenerative
disease of the navicular (distal sesamoid) bone within the hoof, along with its associated
soft tissue structures (i.e., deep digital flexor tendon, impar ligament, and navicular
bursa). Navicular disease is characterized by excessive remodeling of the navicular
bone and a loss of bone mass (Widmer et al., 2000). The etiopathogenesis of navicular
disease is complex and multifactorial, potentially including biomechanical (Wright and
Douglas, 1993), vascular (Colles and Hickman, 1977, Doige and Hoffer, 1983) and
hereditary components (Bos et al., 1986). Vascular changes include arteriosclerosis and
thrombosis of the supplying arteries of the navicular bone (Colles and Hickman, 1977),
while biomechanical changes in the load applied to the navicular bone can lead to
damage and increased remodeling in response to the increased load (Trotter, 2001).

1.3 Bisphosphonate Treatments for Diseases of Bone Remodeling
Management of bone disease, including osteoporosis, was advanced greatly by
the use of bisphosphonate drugs in the late 1960s (Russell, 2011). Bisphosphonates
(BPs) are a chemically stable form of inorganic pyrophosphate, which gives BPs a
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strong specific affinity for calcium, and are composed of two phosphonate groups. BPs
are separated into two classes based on their chemical structure: nitrogen-containing
BPs (e.g., zoledronate, alendronate, and ibandronate) and non-nitrogen containing BPs
(e.g., clodronate, tiludronate, and etidronate) (Russell et al., 1999). Differences in
individual bisphosphonate drugs within each class depend on the compound attached to
the functional, or R-, group (Reszka and Rodan, 2003). Both classes, however, inhibit
osteoclast-mediated bone loss by decreasing osteoclast activity. Nitrogen-containing
BPs are more potent in reducing osteoclast-mediated bone loss than non-nitrogencontaining BPs, and changes in the functional group can also lead to different
physiochemical and pharmacologic modifications. Non-nitrogen containing BPs have
been shown to affect osteoclasts by disrupting intracellular metabolism through
methylene-containing analogs of adenosine triphosphate (ATP) (Frith et al., 2001). This
converts the BP into a toxic metabolite within the cell, and accumulation of this
metabolite inhibits the mitochondrial adenine nucleotide translocase, resulting in the
loss of the mitochondrial membrane potential (Lehenkari et al., 2002). These events
lead to apoptosis of the osteoclast, ultimately inhibiting bone resorption (Reszka and
Rodan, 2003). Nitrogen-containing BPs inhibit osteoclast activity by disrupting farnesyl
diphosphate synthase (van Beek et al., 1999, Fisher et al., 2000), an enzyme in the
mevalonate pathway, that stimulates isoprenylation, which is important in regulating
osteoclast morphology, cytoskeletal arrangement, vesicular trafficking, and membrane
ruffling (Zhang et al., 1995, Chellaiah et al., 2000). There appears to be a dosedependent response of nitrogen-containing BPs, where small concentrations inhibit
osteoclast functions necessary for bone resorption, and high concentrations lead to
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osteoclast apoptosis (Halasy-Nagy et al., 2001). Therefore, nitrogen-containing BPs are
exceptional inhibitors of bone resorption (Kimmel, 2007).
The pharmacokinetics of BPs depends on their classification (Licata, 2005). In
general, BPs are polar compounds, making them poorly, yet rapidly absorbed after
being ingested (Lin, 1996). BPs generally have <2% bioavailability (Yakatan et al.,
1982), and have low plasma protein binding of approximately 30% (Pentikäinen et al.,
1989). The peak serum concentration is obtained quickly following a single oral dose,
within approximately 30 minutes (Laitinen et al., 2000). Most BPs are not metabolized,
and are therefore excreted unchanged (Pentikäinen et al., 1989). BPs have a half-life of
approximately two hours, with bone uptake and renal clearance accounting for the rapid
clearance from plasma (Cocquyt et al., 1999). BPs have a high affinity for exposed
hydroxyapatite, which occurs when bone surfaces are preparing for or currently
undergoing bone resorption (Sato et al., 1991, Lin, 1996), which allows BPs to be taken
up and stored in bone mineral surfaces (Russell et al., 1999), accounting for
approximately 50-60% of the absorbed dose (Licata, 2005). The amount of BP released
from bone depends on the rate of the remodeling process (Gatti and Adami, 1999), as
the BPs are released when the bone matrix is dissolved during the remodeling process.
In addition to inhibiting bone resorption, the non-nitrogen containing BPs
clodronate and etidronate have been shown to produce analgesic effects by entering
neurons through the SLC20/34, and inhibiting glutamate and/or ATP transporters
(Shima et al., 2016). Taken together, bisphosphonates are used in the treatment of
numerous bone diseases in humans, including osteoporosis, Paget’s disease,
hypercalcemia of malignancies associate with myeloma and bone metastases, and
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osteogenesis imperfecta (Russell, 2011), and recently for horses with navicular disease
(Denoix et al., 2003, Whitfield et al., 2016) and other skeletal pathologies [e.g.,
osteoarticular disease (Coudry et al., 2007, Gough et al., 2010, Soto and Barbará,
2014) in veterinary medicine.

1.4 Assessments of Bone Health
1.4.1 Non-Invasive Assessments
In many bone diseases, diagnostic and assessment of disease progression are
critical factors in minimizing negative outcomes for a patient. Historically, obtaining a
bone biopsy was considered the most powerful and informative evaluation technique for
bone assessment (Malluche et al., 1999). However, this method is invasive, and may
not be desirable in a diseased patient. In a human clinical setting, obtaining
informational data, while remaining as non-invasive as possible, is critical in patient care
and disease management. Radiographic imaging has long been the gold standard for
evaluating a variety of pathologies, including bone disease (van de Heijde, 2000).
Radiographs are obtained by photons generated and emitted from a cathode tube that
is collimated to a specific region of interest. As the photons pass through the body, the
photons will be attenuated by tissue according to density, providing levels of exposure
to film for imaging (Drake et al., 2014). Although radiographs are routinely used in
numerous fields of medicine, they can only detect bone losses of greater than 40-50%,
and are therefore not sensitive enough to monitor progression of disease or treatment
(Moyad, 2003).
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For diseases that lead to bone loss, the bone mineral density (BMD)
measurement is the primary diagnostic test and is the gold standard and best predictor
of fracture risk (Hui et al., 1989, Moyad, 2003). BMD produces a relative, overall Tscore that describes the number of standard deviations a patient’s density is from a
group of similarly matched young, normal individuals. There are numerous ways to
obtain BMD, including ultrasound, computerized tomography (Yakatan et al.), dualenergy X-ray absorptiometry (DEXA) and radiographs (Moyad, 2003). Ultrasound is the
use of high frequency acoustic waves produced by piezoelectric material that passes
through tissues without the use of ionizing radiation. As the waves pass, they bounce
back based on tissue properties, are received back through the piezoelectric material,
and are interpreted by a computer, producing a real-time image (Drake et al., 2014).
Because it does not use radiation, ultrasound is a popular imaging modality, specifically
in young adults and children, for monitoring bone disease (Siffert and Kaufman, 2007).
In addition to providing information about bone density, ultrasound can also provide
information about bone quality, such as elasticity and microarchitecture (Prins et al.,
1997). However, there is little information about overall sensitivity and accuracy of serial
measurements (Moyad, 2003). CT scans produce an image by passing a mobile X-ray
tube around the body, creating a series of serially-sectioned two-dimensional images of
the body (Drake et al., 2014). When these images are stacked together, a threedimensional (3D) view is produced. CT is capable of producing extremely highresolution images, but will emit increased radiation to do so. Therefore, although CT has
the highest sensitivity in detecting changes in bone density and trabecular and cortical
bone morphology, it is expensive, requires specialized software for analyses, and can
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produce large amounts of radiation, making it challenging to obtain multiple scans over
an extended period of time (Moyad, 2003). DEXA is a dual energy source of X-ray that
has much higher sensitivity and accuracy, while also decreasing radiation exposure
compared to other forms of radiation imaging. In addition, DEXA is inexpensive
compared to other imaging modalities, making it an ideal technology for serial
measurements, and is the current gold standard for obtaining BMD measurements in a
clinical setting (Moyad, 2003).
In the veterinary clinical setting, the basic radiograph is still one of the most
common diagnostic techniques utilized, but can be combined with additional imaging
modalities, such as nuclear scintigraphy. Nuclear scintigraphy is a radionuclide bone
imaging technique, where the uptake of radiopharmaceuticals, typically technetium99m-labeled diphosphonates for bone, quickly deposits into the bone matrix (McKillop
and Fogelman, 1984). Areas of increased uptake indicate areas of abnormal remodeling
and mineralization. Nuclear scintigraphy is highly sensitive, making it possible to detect
the earliest stages of bone disease; however, due to poor resolution, the specificity is
generally moderate to low (Weller et al., 2001), and limits its use in bone imaging in
both human and veterinary medicine. In systemic abnormal bone remodeling, specificity
is not as important in diagnosis; however, in localized disease where small tissues are
involved, such as navicular disease, specificity is crucial for accurate diagnosis and
characterization. When combined with other imaging, such as radiography, nuclear
scintigraphy is a more useful tool in diagnosing and monitoring abnormal bone
remodeling (Weller et al., 2001), such as with navicular disease (Dyson, 2002) or
osteochondral diseases (Kawcak et al., 2000).
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1.4.2 Invasive Assessments
1.4.2.1 Histology
In research settings, there is less emphasis on patient comfort and longevity, and
more emphasis on obtaining the most sensitive and accurate data possible, allowing for
more invasive data collection methods. In this case, animal models of human disease
are typically used, or animal models of animal disease in veterinary research. The more
invasive technique of obtaining bone biopsies remains the gold standard for
quantification of bone remodeling (Allen, 2003). Though obtaining bone biopsies is more
invasive than most clinical settings prefer, research settings benefit greatly from
numerous parameters available for direct evaluation through the use of histology.
Histology is the process of embedding bone (or any other tissue) samples into a
transparent material and taking thin, serial sections for examination under a microscope
(Recker et al., 2011). Histomorphometry is the measurement of form and structure of a
histologic tissue sample, permitting quantitative analysis of the structure (Duque and
Watanabe, 2011). Previously, bone had to be de-mineralized by strong mineral or
organic acids or acidic buffers, which would rapidly decalcify bone, so thin sections of
bone could be sectioned for viewing (Recker et al., 2011). However, these agents were
known to cause collagen fiber distortions and change the affinity of the tissue structure,
weakening the staining outcomes; therefore, chelating agents, such as ethylenediamine
tetraacetic acid (EDTA), have since replaced previous agents, as they do not have
these negative secondary outcomes (Kiviranta et al., 1980). In the 1950s, however, a
new method of embedding un-decalcified bone into plastic greatly improved bone
research by allowing visualization and assessment of bone with its mineral components
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(Frost et al., 1960). By preserving calcium in bone samples, a new technique of
detecting newly-formed bone and mineralization, called fluorochrome labeling, was
possible. Fluorochrome labeling uses injectable, calcium-binding tetracycline agents to
directly measure bone remodeling dynamics in vivo over time (Frost, 1969).
Tetracycline agents are able to make a complex with calcium that is deposited in areas
of bone mineralization, and becomes permanently fixed within the mineralized matrix
unless disturbed by subsequent remodeling processes (Frost et al., 1961). This
deposition of tetracycline creates a brightly-lit area along the bone surface when
exposed to ultra-violet light, indicating areas of remodeling and mineralization (Perrin,
1965). Fluorochrome bone labeling has since been greatly advanced, with new methods
of labeling bone with up to 7 distinct labels analyzed by specialized spectral image
acquisition software, allowing numerous time points for analyses with decreased tissue
collection requirements (Pautke et al., 2005). In addition to bone remodeling, data on
bone structure and bony cells are analyzed. Various staining solutions are utilized to
highlight certain features, such as tartrate-resistant acidic phosphatase (TRAP) staining
using an enzyme-histochemistry protocol for specific staining of osteoclasts and alkaline
phosphatase (ALP) staining for osteoblasts. There are some limitations of
histomorphometry, however. Overall, slicing sections of the sample is inherently
destructive, and an analysis on a small portion of the skeleton is difficult to generalize to
the rest of the skeleton. Additionally, histomorphometry is a 2D evaluation that
determines 3D parameters through the mathematical discipline of stereology, which
interpolates 3D measurements from 2D measurements using mathematical theorems.
However, despite being an estimation of 3D parameters, there is minimal and
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acceptable error when applied to trabecular bone from ilium samples (Parfitt et al.,
1987, Dempster et al., 2013). Finally, histomorphometry is not the best assessment for
bone mass, due to the 2D nature of the slice, as well as the small relative size of the
section (Duque and Watanabe, 2011).

1.4.2.2 Micro-Computed Tomography
To overcome some limitations associated with histomorphometric analyses,
evaluations are combined with micro-computed tomography (microCT). MicroCT is a
high-resolution form of CT, and is an imaging modality to assess trabecular and cortical
bone morphology with resolutions between 0.5 – 50 μm. MicroCT provides direct
measurements of 3D bone morphology of entire biopsy samples, while providing
excellent specificity and sensitivity using standardized parameters (Bouxsein et al.,
2010). The high resolution increases radiation exposure to the sample; however, in
research settings the specimens are usually taken from animals that are euthanized or
biopsies are collected from live animals. Combined with histomorphometry, a
comprehensive analysis is possible, obtaining information about bony cellular
morphology, bone remodeling dynamics and bone structure (Duque and Watanabe,
2011).

1.4.3 Use of Imaging in Education and Research
With the advancements in medical imaging, anatomical education in both human
and veterinary medicine have both benefited and incorporated many data in the medical
anatomy curriculum. An in-depth understanding of anatomical structures and 3D
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relationships is critical in medical training. High resolution images are obtained and can
be combined to provide visual and technical experience for surgeons in training (Wiet et
al., 2005). For example, high-resolution magnetic resonance imaging (MRI) and
microCT data can be combined to visualize both soft and hard tissues within a sample,
providing a visual and haptic display for a simulation of temporal bone dissection (Wiet
et al., 2005). In addition to computerized visualizations, 3D printing is utilized in
classrooms to provide additional understanding of anatomical structures (McMenamin et
al., 2014). This is especially useful for biological structures or systems that are difficult
to observe or manipulate in cadavers (AbouHashem et al., 2015). In addition to
education, research relies on accurate representation of normal anatomical features,
and benefit from high-resolution, 3D images of biological structures (Duce et al., 2010).
Variation in reported anatomy greatly limits the potential for comparative anatomy
between studies (Duce et al., 2010), and can limit the understanding of normal and
pathological anatomical characteristics (El-Menyar et al., 2017).

1.5 Animal Models of Orthopedic Disease
1.5.1 Selection of Animal Models
Animal models play a crucial role in the understanding, prevention and treatment
of orthopedic disease for both human and veterinary medicine. However, there are
important distinctions between human and animal bone that have implications for
research outcomes (Aerssens et al., 1998). For example, bone repair rates differ
between large and small species, and are inversely related to the species’ position on
the phylogenetic scale, meaning rats have a higher rate of bone regeneration than

17

humans (Martini et al., 2001). In terms of bone composition, human bone is best
represented by canine bone (Aerssens et al., 1998), but canine bone can withstand
significantly higher compression strain than human bone (Kuhn et al., 1989). The use of
quadrupeds as an animal model for human health has been questioned, especially in
relation to differential loading secondary to bipedalism in humans. However, certain
animal models can be selected based on specific criteria pertinent to the study (e.g.,
use of sheep in spine research due to similarities to humans in long axis loading (Smit,
2002)).
The type of animal model selected for research also depends on the aim of the
study. When determining the pathogenesis and pathophysiology of a particular disease,
smaller animals offer quick and cost-effective models than do larger animals. Small
animal models also offer quick screenings of therapeutic interventions and drug safety.
Large animal models, however, offer similar body size to humans and therefore can
make therapeutic or surgical interventions more translatable to humans (Kuyinu et al.,
2016). Thus, researchers must carefully evaluate the goals and anticipated outcomes of
a study when determining the appropriate animal model. When evaluating animal
diseases in veterinary medicine, researchers often have the benefit of using the specific
animal of interest, eliminating the need for a translatable model. However, the
disadvantages of the specific species have to be accounted for, including expense and
the impact of ethical limitations imposed for use of companion animal species.
Therefore, there is usually smaller sample sizes available for research utilizing large
animal models.
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1.5.2 Small Animal Models
The most common small animal orthopedic models include the rat, mouse,
guinea pig and rabbit (Aerssens et al., 1998, Kuyinu et al., 2016). Small animal models
have numerous advantages, including ease of handling, economical housing costs,
short breeding cycles and well known genetics (Histing et al., 2011). For mice, a known
genome make them the perfect model for utilizing genetic manipulations to study
molecular mechanisms. Due to an increase in use of rodents in research, specifically
mice, much information is known about their physiology, and many experimental
protocols and kits are designed for this species. This makes their use more standard
and widely available for additional research, and make them more favorable than a
large animal model that does not have the same available data (Histing et al., 2011).

1.5.3 Large Animal Models
Non-human primates offer valuable information to human medicine due to their
very similar physiological and behavioral characteristics (Kuyinu et al., 2016). Although
non-human primates are the most relevant in terms of mimicking human disease, they
are extremely expensive and are associated with ethical concerns, in addition to the
possible spread of infectious disease, making them a difficult option for many
researchers (Reinwald and Burr, 2008). Therefore, cost-effective alternatives to nonhuman primates, such as ungulate and canine species, are practical, large animal
model substitutes. Although more expensive in terms of management, large animal
models are a necessity in certain research, such as osteoporosis and osteoarthritis
research, due to their longer lifespan, similarities in osteonal remodeling and naturally-
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occurring disease (Reinwald and Burr, 2008). Additionally, it is extremely important that
the animal model develop the desired disease in a similar pathway, such as a loss of
estrogen in an osteoporosis model, so that therapeutic interventions behave similarly in
both the animal model and human. Dogs have long been considered the ideal
alternative to the non-human primate, and have been one of the most studied large
animal models for orthopedic research (Martini et al., 2001). However, the use of dogs
poses a similar ethical concern as do non-human primates due to their companion
status (Rollin, 2006), and the use of dogs has since decreased in research settings.
Pigs have physiological similarities to humans, including sequential skeletal phases of
development. Sheep are another alternative large animal model, and are being used
more frequently in orthopedic research due to their ease of handling (Martini et al.,
2001). Horses are mostly utilized in osteoarthritis research, as they have a similar risk to
humans for developing naturally-occurring osteoarthritis secondary to trauma or as a
result of age, as well as exercise-related osteochondral defects (McIlwraith et al., 2012).
Additionally, they are large enough to use standard imaging modalities. All of these
species are large and expensive, making management and handling more difficult than
small animal models, which are important considerations when initiating research
studies using these models (Gregory et al., 2012).

1.6 Summary and Specific Aims
Overall, bone is a highly complex, active structure that provides organisms with
essential protection and support. Orthopedic research has been greatly advanced by
imaging modalities, allowing researchers to visualize and evaluate bone health, bone
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diseases and therapeutic interventions for both human and veterinary medicine.
Combining evaluation techniques, such as histology and microCT, can overcome the
disadvantages of each technique, and provide comprehensive detail of bone
morphology and cellular structure. In addition, advanced imaging techniques can be
used to provide anatomy depictions for both research and education. Based on this, the
following research has been performed to address currently unknown information in
veterinary medicine regarding bone health in horses and muroid species, and is
summarized in the following aims:

Aim 1: Determine the effect of the bisphosphonates tiludronate on normal bone
turnover, bone morphology and bony cells in skeletally immature horses via microCT
and histomorphometry.
Summary: To test the effect of tiludronate on bone, biopsies from the tuber
coxarum were taken from ten horses aged two - five years old. A baseline biopsy was
collected at Day 0, and horses were then administered either tiludronate or saline.
Horses were administered oxytetracycline as a fluorescent bone label at Day 47 and 57
for evaluation of bone remodeling. A second biopsy was collected at Day 60 from the
contralateral tuber coxarum. Samples were fixed and scanned by microCT for
evaluation of trabecular bone morphology. The biopsies were then prepared for
decalcified and un-decalcified histology for evaluation of bony cells, bone morphology
and bone remodeling following standard techniques and nomenclature. This aim will
establish if tiludronate affects normal bone structure and remodeling in skeletally
immature horses. The hypothesis is that tiludronate will reduce osteoclast numbers and
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function, resulting in increased bone volume and decreased bone remodeling in young
horses.

Aim 2: Determine the effect of clodronate on normal bone turnover, morphology and
repair in skeletally immature horses via microCT and histomorphometry.
Summary: Aim 2 utilized the study design and techniques as outlined in Aim 1. In
brief, biopsies were taken from nine horses aged two – four years old; a baseline biopsy
(Day 0), a contralateral biopsy (Day 60), and a re-biopsy of the initial site (Day 60R),
providing a biopsy after a bone defect. Clodronate or saline was administered
immediately following Day 0 biopsy collection. Preparation and assessments were
identical to Aim 1. Additionally, the Day 60R biopsy was scanned via microCT and then
prepared for decalcified histology. This aim will first establish our equine model as an
adequate model of bone repair. Subsequently, this aim will determine if clodronate
impacts bone structure and repair in skeletally immature horses. The hypothesis is that
clodronate will result in increased bone formation in an equine model of bone healing,
as well as reduce osteoclast numbers and function, resulting in increased bone volume
and decreased bone remodeling in young horses.

Aim 3: Characterize the anatomy of the mouse tarsus and clarify the presence and
number of bones within this region in normal laboratory mice.
Summary: Bony anatomy of the tarsi from two strains of commonly used
laboratory mice (i.e., C57/Bl6 and BalbC) were evaluated for bony anatomy
characteristics via microCT. This anatomy was compared to selected outgroups,
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including the closely-related laboratory rat (Sprague Dawley®) and the more distantly
related wild white-footed mouse (Peromyscus leucopus). Representative mouse tarsi
were selected for routine decalcified histology preparation, where serial, sagittal
sections were taken through the mid-tarsus. The hypothesis is that normal laboratory
mice have a fusion of the central and tarsal bone III, which is not present in other
outgroup species evaluated.
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CHAPTER 2.
INFLUENCE OF TILUDRONATE ON BONE CELLS, MORPHOLOGY
AND REMODELING IN YOUNG HORSES1
2.1 Introduction
Tiludronate disodium (Tildren, Ceva Animal Health LLC, Lenexa, KS, USA) is a
bisphosphonate drug that is licensed for use in horses to reduce lameness associated
with navicular disease (Denoix et al., 2003, Whitfield et al., 2016). Tiludronate has a
high affinity for bone (Henneman et al., 2008) and reduces osteoclastic activity (David et
al., 1996), resulting in inhibition of bone resorption and subsequent uncoupling of the
balanced remodeling process (Murakami et al., 1995, David et al., 1996, Kamm et al.,
2008). Tiludronate has been shown to have potential effectiveness to treat
musculoskeletal conditions other than navicular disease, such as distal tarsal joint
osteoarthritis (Gough et al., 2010), thoracic and lumbar vertebral arthritis (Coudry et al.,
2007) and dorsal metacarpal disease (Carpenter, 2012). However, these studies all
report data on clinical outcomes (e.g., improvement in lameness), and not the effect on
bone. Similarly, clinical studies have shown a reduction in lameness associated with
navicular disease following tiludronate treatment (Denoix et al., 2003, Whitfield et al.,
2016). One barrier to the field is currently a lack of data regarding the direct impact on
bone remodeling kinetics in horses. Only a single study has attempted to evaluate
tiludronate’s direct impact on bone; however, it was unsuccessful (Delguste et al.,
2007). In addition, tiludronate has been administered to young horses as a treatment for
dorsal metacarpal disease (Carpenter, 2012), despite their still having to undergo a

1

Parts of this chapter previously appeared as Mitchell, C.F. et al., Assessment of Tuber
Coxae Bone Biopsy in the Standing Horse. Vet Surg (2017) DOI: 10.1111/vsu.12603.
Reprinted by permission of John Wiley and Sons via RightsLink.
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tremendous amount of bone remodeling as a part of normal bone growth (Müller et al.,
1998). Despite the potential impact of tiludronate on normal bone remodeling kinetics, a
detailed study has not been performed to determine if tiludronate negatively affects
normal bone remodeling in young horses.
The gold standard for bone analyses are histomorphometry (Müller et al., 1998)
and microCT (MacNeil and Boyd, 2007), both of which require bone biopsies. The tuber
coxarum has been reported to be the easiest site for bone biopsy acquisition in the
horse and is a region that was found to have consistently higher levels of tiludronate in
comparison to other bones (Delguste et al., 2011). A recently published study by the
authors has shown the tuber coxarum as a site to obtain reliable bony samples in a nonterminal equine model that are consistent in size and of adequate quality to evaluate
trabecular bone using both histomorphometry and microCT (Mitchell et al., 2017).
Therefore, the aim of this study was to evaluate the effect of tiludronate on bony
cells, bone morphology and remodeling in skeletally-immature, clinically healthy horses.
This was accomplished by evaluating bone biopsies, obtained from the tuber coxarum
using a previously published surgical technique (Mitchell et al., 2017), via microCT and
histomorphometry. We hypothesized that tiludronate administration would result in
increased bone volume, decreased osteoclast numbers and activity, and increased
bone apposition when compared to control samples.

33

2.2 Materials and Methods
Study Design
The experimental protocol was approved by the Louisiana State University
Institutional Animal Care and Use Committee (IACUC) (Protocol #14-069). Ten clinically
healthy Thoroughbred horses (two - five years of age and weighing between 409 kg and
570 kg) were obtained via donation to the Louisiana State University Equine Health
Studies Program. Medical history of the horses was unknown at the time of donation;
however, prior to enrollment in the current study, all horses underwent at least a twoweek isolation and washout period following donation. Horses were randomly assigned
using a coin flip to either a treatment (n=5) or control group (n=5). The surgeon, who
was not involved in subsequent analyses, was not masked to treatment groups. All
personnel who took part in the data collection and analysis were masked to treatment
groups.
Bone biopsies were taken from each horse at Day 0 (baseline before treatment)
and Day 60 (60 days post-treatment) (Figure 2.1). This time frame was determined by
previous studies that showed a positive effect of tiludronate administration in horses 60
days post initiation of treatment (Denoix et al., 2003, Coudry et al., 2007, Gough et al.,
2010). The right or left tuber coxarum was randomly selected, via coin flip, for the first
biopsy (outlined below in “Surgical Procedure”). Immediately following the initial biopsy
surgery (Day 0), each horse was administered tiludronate (1 mg/kg, diluted in 1L of
0.9% saline, IV) or equal volumes of saline. The tiludronate solution was administered
over 90 minutes using an IV fluid pump. The horses stood in the stocks during this
infusion and were monitored for signs of colic. Sixty days later, the contralateral tuber
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coxarum was biopsied in the same manner. Prior to the second biopsy, oxytetracycline
(Vetrimycin 100, VetOne, Boise, ID, USA) was administered at Day 47 and Day 57 as a
fluorochrome label to identify bone remodeling parameters. Biopsies were evaluated
with microCT and histomorphometry for changes in bone morphology and remodeling
rates, as outlined below under “MicroCT” and “Histology.”

Figure 2.1 Tiludronate study design schematic of time line, outlining biopsy collection
and treatment administration. Abbreviations: Contra., Contralateral; Ipsi., Ipsilateral.
Study Horses
Thoroughbred horses, as outlined above under “Study Design”, were included if
they were free from outward musculoskeletal disease and clinically healthy, as
assessed by a boarded veterinary surgeon (CFM) during a physical exam, and included
seven geldings and three fillies with a mean age of 3.5 years (control age: (mean ± SD)
3.4 ± 1.14 years; weight: 500.6 ± 44.8 kg; treated age: 3.6 ± 1.34 years). Sample sizes
were influenced based on donation availability, and all eligible horses were considered.
Additionally, if eligible horses became available during the course of data collection,
they were evaluated and included in order to maximize sample size. Throughout the
study, they were housed in individual stalls following the biopsies and then turned out in
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groups in pastures. They were fed free choice hay and water, with grain being provided
twice daily.
In addition to the aforementioned horses, biopsies were also obtained from three
additional horses euthanized for non-musculoskeletal related reasons at the Louisiana
Disease and Diagnostic Laboratory (LADDL). These were samples of convenience,
obtained at necropsy from horses not included in this study. These horses were aged 9
months, 1 year, and 25 years, and were used to compare histopathological changes
within the biopsies with age. The samples were obtained using the same surgical
technique, as described below, but were not enrolled in the pharmacologic evaluations.

Surgical Procedure & Treatment
Horses were sedated with intravenous (IV) xylazine (Xylamed, Bimeda,
Cambridge, ON Canada) (0.35 to 0.5 mg/kg). The surgical method has been previously
published in detail (Mitchell et al., 2017). In short, the biopsy site was centered on the
proximal palpable protuberance of the tuber coxarum. A rectangular region
(approximately 10 cm X 10 cm) was clipped around the tuber coxarum and then
aseptically prepared. Lidocaine (Lidocaine 2%, VetOne, Boise, ID, USA) was injected
subcutaneously, deep to the proposed incision site in a vertical line, centered on the
palpable tuber coxarum, extending 4 cm proximal and distal to that palpable point and
then deeply, adjacent to the periosteum of the tuber coxarum. The horse was further
sedated with detomidine hydrochloride (Dormosedan, Zoetis, Kalamazoo, MI, USA) (3
to 5 mg IV) and butorphanol tartrate (Torbugesic, Fort Dodge, New York, NY, USA) (3
to 5 mg IV) prior to making the skin incision (Mitchell et al., 2017).
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A 6-8 cm, vertically oriented incision was made over the tuber coxarum (Figure
2.2A), and dissected to expose the cranial, caudal, proximal and deep margins. The
periosteum was incised with a #15 blade in a cranial to caudal direction on the lateral
edge of the tuber coxarum, at least 1 cm distal to the proximal portion of the
protuberance. An oscillating saw was used to transect the protuberance of the tuber
coxarum, with the saw blade angled either parallel to the ground or slightly dorsally,
depending upon the position of the limb and the horse’s pelvic anatomy. In order to limit
thermal damage, the saw blade was continuously lavaged with saline. Depending upon
the direction of the saw cut, the bone biopsy (Figure 2.2B) was either removed, or
detached from soft tissue prior to removal. The excised section of bone representing the
biopsy was at least 1 cm tall, with the width and length of the biopsy dependent on each
horse’s pelvic anatomy. The goal was to obtain the largest biopsy possible without
cutting into the iliac crest on the deep border of the tuber coxarum. If necessary, the
horizontal cut was moved distally and the saw blade angled in a more proximal direction
to produce a biopsy of suitable size. The surgery site was lavaged, and the
subcutaneous tissue was sutured with 2-0 polyglactin 910 in a simple continuous
pattern. The skin was sutured using 0 polypropylene in either a Ford interlocking or
cruciate pattern. An aluminium based bandage spray (Aluspray, Neogen Corporation,
Lexington, KY, USA) was applied to the surgery site and a lidocaine patch (Lidocaine
Patch 5%, Qualitest, Huntsville, AL, USA) was then applied over the incision (Mitchell et
al., 2017).
Following the initial biopsy (Day 0 to 1), horses were stalled for at least 24 hours
and monitored every 2 hours over the first 24-hour period using a visual pain score
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Figure 2.2 Bone biopsy from the tuber coxarum in a horse. A) The incision is centered
over the palpable dorsal protuberance of the tuber coxarum. The excised piece of tuber
coxarum is directly above the saw blade, with a small amount of connective tissue on its
superficial edge. Cranial to the left of image, proximal to the top of image. B) Bone
biopsy harvested. Cut surface facing up, resting on a 10.1 X 10.1 cm gauze square.
MicroCT

(Doherty and Valverde, 2006). After 24 hours, horses were returned to their respective
pastures and checked daily for signs of lameness or incisional complications until suture
removal at 14 days post biopsy. At Day 47 and 57 post biopsy, the horses were treated
with 25 mg/kg of oxytetracycline administered slowly IV. Sixty days after the initial
biopsy, the contralateral tuber coxarum was biopsied using the same surgical methods
as described above. However, after surgery, horses were administered flunixin
meglumine (Prevail, Bimeda, Cambridge, ON, Canada) (1.1 mg/kg IV) as an additional
analgesic. Surgical aftercare was identical to above from post-surgery to 14 days later
when the sutures were removed.
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MicroCT
Following biopsy, tuber coxae samples were dissected free from tissue and fixed
in 10% non-buffered formalin for seven days, then transferred to and stored in 70%
ethanol at 20˚C. Samples were placed in holders with 70% ethanol for scanning by
microCT (Scanco model 40, Scanco Medical AG, Basserdorf, Switzerland). Biopsies
were scanned at 55kV, 0.3-second integration time, with a 30 µm voxel size in plane
and a 30 µm slice thickness. The region of interest was determined for trabecular bone.
The proper threshold for image segmentation was tested, with the same threshold being
used throughout the experiment. Trabecular bone was evaluated for bone volume (BV),
total volume (TV), BV/TV, tissue mineral density, trabecular number (Tb.N), trabecular
thickness (Tb.Th), trabecular spacing (Tb.Sp), connectivity density (Conn.D) and
structural model index (SMI) based on established procedures and nomenclature
(Bouxsein et al., 2010).

Histology
Following microCT evaluation, biopsies were prepared for histology. Day 0
biopsies were prepared for decalcified histology, and Day 60 biopsies were prepared for
undecalcified histology so visualization of fluorochrome labels was possible. Due to
differences in preparation techniques between decalcified and undecalcified histology,
and size of slides used for each, histological preparation of both sets of biopsies differed
slightly. However, care was taken to ensure sections from each biopsy were taken in
the same location and plane of section, regardless of preparation method. Day 0
biopsies were decalcified with 10% ethylenediaminetetraacetic acid (EDTA) and
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prepared for routine paraffin embedding. In order to fit on glass histological slides, Day
0 biopsies were split in half and embedded separately. This resulted in 6 – 8, 4 µm thick
sections per biopsy that were stained with hematoxylin and eosin (H&E). Day 60
biopsies were prepared intact for undecalcified histology and two, 45-60 µm thick
sections were produced. The first was stained with Stevenel’s Blue and Van Gieson’s
picro fusion for evaluation by static histomorphometry, and the second section was left
unstained for evaluation by dynamic histomorphometry. Although histological slides for
Day 0 and Day 60 biopsies were prepared differently for ease of handling, all bony
features were easily discernable and comparable in both sets of slides, as outlined in
Figure 2.3 (Dempster et al., 2013).
All biopsy sections were evaluated for quality under light microscopy as
previously described (Steiger et al., 1999). In short, cortical and trabecular bone in each
section were evaluated using a semi-quantitative scale whereas tissue was determined
to be useless (0), poor (1), or good (2) quality. Three individuals (including one boarded
veterinary pathologist, one established orthopedic researcher and one graduate
student), evaluated each slide. Some biopsies had multiple sections to evaluate and all
sections generated a score that was then averaged for each biopsy.
All bone histomorphometry evaluations were performed using histomorphometry
software (Osteomeasure© Bone Histomorphometry System, Osteometrics, Inc.,
Decatur, GA, USA) following standard procedures and nomenclature (Dempster et al.,
2013). Static histomorphometry parameters included direct measurements of: BV,
marrow volume (Ma.V), bone surface (Crook et al.), eroded surface (ES), mineralized
surface (Md.S), osteoblast surface (Ob.S), osteoblast number (Ob.N), osteoclast
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number (Oc.N), osteoclast surface (Oc.S) and remodeling surface (RS). Indirect
measurements included: Tb.N, Tb.Th, Tb.Sp and the aforementioned direct
measurements

standardized

to

respective

areas

and

volumes.

Dynamic

histomorphometry included mineralizing surface per bone surface (MS/BS), mineral
apposition rate (MAR) and the bone formation rate per bone surface (BFR/BS).

Figure 2.3 Labeled histological sections of bone biopsies. Representative A) decalcified
and B) un-decalcified histological sections of biopsy 2 (Day 60), highlighting similar
trabecular bone features. Abbreviations: B, bone; BM, bone marrow. Black arrows =
osteoblasts; white arrows = osteocytes.
Statistics
To evaluate slide quality, trabecular bone quality scores were averaged and the
standard deviation was calculated. To evaluate the effect of tiludronate on bone,
microCT and histomorphometry data were analyzed using independent analyses
between treatment groups, as well as dependent analyses between biopsies. Data were
tested for normality using the Shapiro-Wilk test and depending on normality, either
parametric or non-parametric analyses were used (i.e., Student’s t-test or related
samples Wilcoxon signed rank test, respectively). A related-sample test was used to
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evaluate changes from biopsy 1 (Day 0) to biopsy 2 (Day 60) within the control or
treated horses. An unrelated-sample test was performed to evaluate difference between
treated and control horses within biopsy 2. Statistical analyses were performed using
commercially-available software (SPSS, version 22, IBM Corporation, Armonk, NY,
USA), and p-values of <0.05 were considered significant.

2.3 Results
Surgical Technique
Horses received between 408 – 500 mg (mean ± SD, 474.6 ± 38.6 mg) of
tiludronate based on weight. Only one of the ten horses in the study experienced
incisional dehiscence, but this complication resolved with minimal medical intervention.
All of the other 19 biopsies healed uneventfully, with no horses displaying any rear limb
lameness or ratable discomfort at any time over the duration of this study. All biopsies
obtained were adequate for all analyses (mean volume of 3123.72 mm3 ± 1495.37 mm3
(SD) as measured via microCT) (Mitchell et al., 2017).

MicroCT
The biopsies were consistent in size and shape between both biopsies and treatment
groups (Figure 2.4). No significant differences in TV were identified between treatment
groups or biopsy as evaluated by microCT (Figure 2.5). Overall, tiludronate did not
significantly alter bone morphology parameters after 60 days when compared to saline.
In addition, there were no significant differences in morphology parameters between
biopsies within treated horses or control horses (Figure 2.5).
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Figure 2.4 Representative Day 0 bone biopsies for control (A,C) and treated (B,D)
horses, showing the entire biopsy, excluding cortical bone (A,B), and a visuallysectioned view (C,D), highlighting the trabecular bone architecture. The ventral face is
the surgically-cut surface. Bar = 2 mm.
Histopathology and Slide Quality
Microscopic examination showed all sections consisted of irregularly triangular, domeshaped, or rectangular sections of mature bone containing variable amounts of compact
cortical bone and attached ligaments, tendon and associated skeletal muscle, lamellar
trabecular bone and marrow spaces. The quality of the trabecular bone within all
biopsies was good (Figure 2.6), with adequate bony tissue for evaluation trabecular
bone.
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Figure 2.5 Summary data (mean ± SD) of bone structure and remodeling parameters from biopsy 1 (Day 0) and biopsy 2
(Day 60) for microCT analyses, static histomorphometry analysis and dynamic histomorphometry analysis in control (n=5)
and treated (n=5) horses. Abbreviations: BV/TV, bone volume fraction (bone volume/total volume); Tb.Th, trabecular
thickness; Tb.N trabecular number; BS/BV, bone surface/bone volume; Ob.N/TA, number of osteoblasts per tissue area;
Oc.N/TA, number of osteoclasts per tissue area; sL.S/BS, single label surface per bone surface; dL.S/BS, double label
surface per bone surface; MAR, mineral apposition rate. aSignificant (P ≤ 0.05) difference between values with the same
letter superscript. P-value results from related samples Wilcoxon Signed Rank Test.
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Figure 2.6 Mean (±SD) histological bone biopsy scores from each horse enrolled in the
study. The quality scores were categorized as follows: useless (0), poor quality (1),
good quality (2).
Sections contained variable amounts of artifact from collection, including
presence of bone dust, mild hemorrhage, coagulative necrosis of skeletal muscle or
bone and rare trabecular fractures. In most sections, these artifacts were present at the
margins of the sections examined, only rarely extending into more central aspects of the
sections, and therefore did not affect interpretations of the majority of the tissue sample.
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Any area of compromised architecture or artifact did not extend any more than 2 mm
away from the cut surface in any of the biopsies.
Most horses (8/10) and most sections (12/18) showed variable sized foci of mature
hyaline cartilage present scattered throughout the endocortical spaces. These were rare
(one - three small islands) in some sections, but numerous in others. Foci ranged from
irregularly round or oval, to polygonal to linear, and were frequently surrounded by
variable amounts of mature, lamellar trabecular bone. Occasionally, within the round to
oval foci, the hyaline cartilage surrounded an open central region containing blood
vessels within adipose and loose fibrous connective tissues (Figure 2.7A). In some
cartilage islands, there were variably sized regions of necrosis or areas of
mineralization. Occasionally, the chondrocytes within the viable areas of cartilage
formed distinct rows and demonstrated ordered chondrocyte maturation, similar to that
seen in physeal growth plates (Figure 2.7B). These features were especially prominent
in more linear foci of hyaline cartilage. In some sections, there were more subtle foci of
mineralized cartilage completely surrounding by and embedded in mature, lamellar,
trabecular bone (Figure 2.7C). There were variable amounts of mature hyaline or
fibrocartilage blending with the adjacent ligament at the margins of most sections along
the periosteal surface of the cortical bone, consistent with ligament attachment sites.
Occasionally, irregularly linear tongues of cartilage extended from these regions into the
adjacent marrow spaces (Figure 2.7D). In addition to the apophyses, these sections
contained individual foci of hyaline cartilage within the endocortical spaces. Some of
these foci were closely associated with the growth plate and/or hyaline cartilage within
areas of ligament attachments.
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Figure 2.7 Histologic images of cartilage foci within endocortical spaces. A) Hyaline
cartilage with central region composed of loose fibrous connective and adipose tissues
(bounded by arrowheads) containing numerous blood vessels (red arrows). B) Cartilage
with chondrocyte maturation (black arrows). C) Mineralized cartilage foci (bounded by
green arrowheads) embedded within mature trabecular bone. D) Cartilage tongues
(blue arrows) extending from a site of ligament attachment (yellow arrowheads) into
endocortical space.
Additional samples from 3 horses of a range of ages (i.e., 9 months, 1 year, 25
years) not included in the experiments were examined for comparison to the study
horses. The sections from the 9-month and 1-year-old horses were histologically similar
and contained linear, mature growth plate cartilage within the endocortical space,
consistent with an apophyseal growth plate. These apophyses exhibited normal
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chondrocyte maturation including distinguishable resting, proliferative, hypertrophic, and
mineralization zones (Figure 2.8).
In addition to the apophyses, these sections contained individual foci of hyaline
cartilage within the endocortical spaces, similar to those present in the previously
described study samples. Some of these foci were closely associated with the growth
plate and/or hyaline cartilage within areas of ligament attachments. In one section of the
1-year-old horse, there was an area within the peripheral cortical hyaline cartilage that
demonstrated orderly chondrocyte maturation similar to that within the apophysis
(Figure 2.8B). In contrast to the study animals, the marrow spaces in these two animals
was often highly cellular.
In the 25-year-old horse, there was a single small focus of mineralized cartilage
embedded within trabecular bone. There were no other regions of hyaline cartilage
within the endocortical space. At the ligament attachment sites associated with the
cortical bone, there was less cartilage present than in the previously described slides.

Figure 2.8. Histologic images from juvenile horse demonstrating active bone formation.
(A) Histologic image containing an apophyseal growth plate with distinct resting,
proliferation, hypertrophic, and mineralization zones; (B) Histologic image
demonstrating a region of bone formation associated with the hyaline cartilage at a
ligament attachment site.
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The cartilage present consisted of fibrocartilage, rather than hyaline cartilage. The
marrow spaces contained adipose tissue and no cellular bone marrow.

Histology
As evaluated using static histomorphometry, no significant differences were
identified between treatment groups. When comparing biopsies within each treatment
group, tiludronate significantly decreased trabecular thickness (p=0.02) and increased
BS/BV ratio (p=0.048) when comparing Day 60 biopsies to Day 0 biopsies. Some
measurements were significantly different when comparing the Day 60 biopsy to the
Day 0 biopsy for the saline group: a decrease in RS/BS (p=0.04), decrease in BS/TV
(p=0.04), decrease in Oc.N/TA (p=0.04) (Figure 2.5) and a decrease in Oc.S/BS
(p=0.04).
As evaluated using dynamic histomorphometry, after 60 days, tiludronate did not
significantly alter bone remodeling parameters when compared to saline. Overall, bone
apposition rates and bone turnover was very similar between treated and control groups
(Figure 2.5).

2.4 Discussion
This report describes the effect of a single administration of tiludronate on bony
cells, trabecular bone morphology and bone remodeling in ten clinically healthy, young
horses. A previous study utilizing a bone biopsy model attempted to elucidate changes
in bone morphology secondary to tiludronate treatment in horses, but, the samples
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obtained were inadequate for evaluation of bone morphology and remodeling (Delguste
et al., 2011). Thus, to our knowledge, this is the first reported study evaluating the
cellular and structural effect on bone secondary to tiludronate administered in horses.
There were no significant effects of tiludronate (1 mg/kg, IV) on bony cells or bone
structure and remodeling parameters 60 days after a single administration in young
horses. Although a few parameters were significantly different for the control group, we
believe that these are changes that could occur during normal bone turnover in young
horses, and these select changes do not make substantial biological sense when all
variables are considered. It is possible, however, that these are select bony changes
that occur during normal bone turnover in young horses, and tiludronate prevented
similar changes from occurring. No differences were noted between treatment groups
within the same biopsy. Although there was a significant increase in trabecular
thickness between biopsies in horses treated with tiludronate, as determined by static
histomorphometry, this change was not corroborated with microCT evaluations, which
provides a more comprehensive evaluation of bone morphology within the biopsies.
It is possible that the time frame (60 days) evaluated in this study was not long
enough to evaluate overall changes in bone remodeling. However, this time frame was
selected based on the only published data regarding the effect of tiludronate on horses,
which found a positive effect of tiludronate after 60 days (Denoix et al., 2003, Coudry et
al., 2007, Gough et al., 2010). In addition, a study evaluating bone remodeling in horses
following treatment with phenylbutazone, which, unlike tiludronate, is not utilized as a
treatment for diseases of bone remodeling, found significant changes in MAR using
similar sample sizes after only 30 days (Rhode et al., 2000). Therefore, if tiludronate
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was to have an impact on bone remodeling in young horses at the dose given, it would
be expected that normal bone apposition rates in horses should be at least minimally
affected by tiludronate within the timeframe of the present study. However, it is possible
that diseased bone, characterized by abnormal bone remodeling, could be impacted by
tiludronate administration more than the results shown in this study on normal bone. A
study that identified significant improvements in lameness secondary to distal tarsal joint
osteoarthritis 60 days post treatment with tiludronate also identified significant
reductions in periarticular osteophyte formation at that time point, as evaluated by
radiographs, indicating a potential influence on bone remodeling in horses (Gough et
al., 2010). Therefore, these data also support the chosen time point at which to identify
potential changes in bone microarchitecture. However, future studies including
additional time points post treatment would be required to confirm whether tiludronate
has a significant impact on bone morphology. As such, more recent data evaluating
effectiveness of tiludronate administration on lameness associated with navicular
disease as evaluated by more objective force platform analyses found significant
improvements 120 and 200 days post treatment, but not after 60 days (Whitfield et al.,
2016).
Due to the nature of a pilot study, there was a low sample size of 5 horses per
group. Therefore, the effect of tiludronate on bone remodeling and structure may not
have been apparent in the data presented here. Overall, it is possible that tiludronate
has a small effect that was not identified in the present study. However, a difference to
some degree was expected, despite the low numbers, given the power of tiludronate as
a modifier of bone remodeling in numerous other species (Rhode et al., 2000). The fact
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that there was no difference between treatment groups or biopsies within the same
horse warrants further investigation into the efficacy of tiludronate as a treatment for
diseases of bone remodeling in the horse at the current dosage recommended.
Tiludronate therapy is widely used in the veterinary clinical setting to treat
disorders involving abnormal bone remodeling, including distal tarsal joint osteoarthritis
(Gough et al., 2010), thoracic & lumbar vertebral arthritis (Coudry et al., 2007) and
dorsal metacarpal disease (Carpenter, 2012). The efficacy of tiludronate has been
shown in young animals in other species, including a reduction of trabecular bone
resorption adjacent to growth plates and increased bone density in skeletally immature
rats and baboons (Geusens et al., 1992). Tiludronate has been previously evaluated for
pathological bone changes in horses aged 4 years and older (FOI, 2014); however,
despite the manufacturer’s recommendation to avoid administration of tiludronate to
horses less than four years of age, clinicians are administrating this drug to horses that
are younger than four years of age as a treatment for dorsal metacarpal disease
(Carpenter, 2012). It is well known that younger horses undergo more rapid bone
remodeling than skeletally mature adults (Goyal et al., 1981), so this study aimed to
also evaluate the effect of tiludronate administration in young horses, where negative
impacts on normal bone remodeling could result in significant clinical outcomes in
young equine athletes. While the current study population included horses four and five
years of age, biopsies from all horses within the study included evidence of an open
apophysis for the tuber coxarum (Mitchell et al., 2017), indicating some degree of
skeletal immaturity. Additionally, the same biopsy taken from a 25-year-old mare, which
can be reasonably assumed to be skeletally mature, showed no presence of an

52

apophysis or retained hyaline cartilage foci. Thus, it appears that there is likely complete
closure of the apophyseal growth plate and transition of the superficial hyaline cartilage
to mature fibrocartilage associated with skeletal maturity, which was not present in the
evaluated horses. Additionally, although subjective and not quantitatively evaluated, one
evaluator noticed an increase in the size and number of cartilage foci in samples in the
younger horses. However, due to the large age gap between the horses included in the
study and the 25-year-old evaluated, it is unclear when the apophyses in the tuber
coxarum disappear. Horses in the current study were also not strictly age-matched;
however, the means and standard deviations for each group were almost identical. In
addition, dependent analyses comparing biopsies within each horse were performed,
thereby serving as a more robust analysis of changes secondary to treatment. As
outlined above, we did not see any influence on bone remodeling or morphology in this
young population. However, due to the small sample sizes for each age included in the
study and the known effect of age on bone remodeling parameters, there cannot be
definitive conclusions based on age. In addition to a larger number of horses, a smaller
range of ages in horses may result in a significant effect on bone morphology
parameters.
The iliac biopsy location utilized in the study was chosen for multiple reasons,
despite the dissimilarities in architecture and biomechanics to weight bearing bones
found in the equine distal limb, such as the metacarpal bones. Most importantly, the
tuber coxarum is an easily accessible location that allowed for a non-terminal biopsy
model in the equine, and provides the opportunity for multiple biopsies from the same
horse over set time points (Mitchell et al., 2017). Various sites for bone biopsy have
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been described in standing sedated, anesthetized and euthanized horses (Delguste et
al., 2011). These locations include the sternebrae, ribs, tuber coxae, the third
metacarpal bone, and the fourth tarsal bone (Misheff et al., 1992, Steiger et al., 1999,
Désévaux et al., 2000, Delguste et al., 2011). Biopsies obtained in these studies have
ideally been as small as possible due to the relative size of the bone being sampled
(ribs) or due to the load-bearing nature of the bone (metacarpus) (Firth, 2004). Biopsies
obtained from weight bearing bones, such as the metacarpals and tarsal bones,
deemed of adequate size for histologic examination would likely result in lameness or
euthanasia of the horse. In addition, these samples would provide little, if any,
trabecular bone for examination, as these bones are composed of predominantly
cortical bone. Larger biopsies from non-weight-bearing bones provides more data for
consistent histological and architectural examination, as shown in this study.
Despite the differences in biomechanics, bone remodeling of the tuber coxarum
has been shown to accurately predict the effect of alendronate, another form of
bisphosphonate, on non-homogenous skeletal locations in the body (i.e., vertebral
column) (Mashiba et al., 2005). This location was chosen for the biopsy site for the
additional reason that it has been shown that bisphosphonates accumulate at the
highest density in tuber coxae when compared to other bones in the equine, including
bones that experience more biomechanical stress, such as the 3rd metacarpal, rib and
cuboid bone (Delguste et al., 2011). An added benefit of this biopsy technique was the
relatively large biopsy size, which allowed multiple study endpoints to be utilized. The
second biopsy was prepared for undecalcified histology in order to preserve the
fluorescent label, which required different preparation than the initial biopsy received.
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Although preparation methods varied, methods of analyses and outcome measures
were identical for both preparation methods of static histomorphometry sections
(Dempster et al., 2013).
It is important to recognize that this technique for biopsy has potential to include
the apophyseal growth plate or remnants thereof, particularly in younger horses. The
specific apophyses in the bones of the pelvis in the horse are not well described and the
presence of an apophysis in the tuber coxarum has not been substantiated in the
literature of domestic quadrupeds. The identification of an apophysis in the tuber
coxarum is an important finding and the presence of cartilaginous foci should be noted
for future studies using this biopsy method as it may bias assessment of trabecular
bone that rely on counts of trabecular number and spacing. However, the presence of
these foci do provide a potentially unique opportunity for investigators examining
changes in bone growth and physeal activity in horses.
In conclusion, this study describes a simple tuber coxarum biopsy procedure for
horses that is well tolerated and produces samples large enough to be sectioned
multiple times, permitting several methods of analyses to evaluate bone morphology
and remodeling in a non-terminal model. It appears that tiludronate does not have a
substantial impact on normal bone remodeling kinetics and morphology in young horses
60 days post treatment. Overall, tiludronate does not appear to impact bone remodeling
parameters in young horses, and has minimal to no effect on bone morphology
parameters after 60 days.
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CHAPTER 3.
INFLUENCE OF CLODRONATE ON BONE CELLS, MORPHOLOGY, REMODELING
AND HEALING IN YOUNG HORSES
3.1 Introduction
Recently, the FDA approved the use of Clodronate disodium (Osphos, Dechra,
Ltd., Staffordshire, UK) as a treatment for navicular disease in the horse (FOI, 2014).
Clodronate is a non-nitrogen containing bisphosphonate that reduces osteoclastic bone
resorption by causing osteoclast apoptosis (Lehenkari et al., 2002). Clodronate is
similar to tiludronate, which has been used extensively to treat conditions associated
with bone remodeling, such as navicular disease (Denoix et al., 2003, Whitfield et al.,
2016) and tarsal osteoarthritis (Gough et al., 2010). However, unlike tiludronate,
clodronate has been shown to have an analgesic effect by acting on glutamate and/or
ATP-related pain transmission pathways (Shima et al., 2016). The Freedom of
Information (FOI) Summary (FOI, 2014) reports on the clinical outcome in a group of
horses diagnosed with navicular disease, treated with either clodronate or saline. At 56
days post-treatment, 68 of 86 clodronate-treated horses had improved by one score of
the American Association of Equine Practitioner (AAEP) lameness scale, compared to 1
of 28 saline-treated horses (FOI, 2014). However, it is unclear whether the reduction in
lameness in the aforementioned study (FOI, 2014) is due to clodronate treatment’s
effect on pathological bone remodeling, or its analgesic potential.
The FOI summary describes the effects of clodronate on bone mineral content,
cortical bone strength and bone marrow evaluation evaluated by radiographic
photometry, mechanical testing and histopathology, respectively, in normal horses.
They reported no difference in these parameters between treated and saline controls at
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6 months (FOI, 2014). However, the methods regarding how bone density data were
obtained were not stated, and given the poor sensitivity of radiographs to determine
bone density (Moyad, 2003), it is uncertain whether there was or was not an effect on
bone in this cohort. Despite its known effect on bone remodeling rates in other species,
the effect of clodronate on bone healing, especially in the horse, is unclear. In animal
models, clodronate has been found to not alter endochondral bone formation within the
callus or epiphyseal plate of rats (Nyman et al., 1996, Madsen et al., 1998), but reports
show conflicting alterations to callus and bone properties, including no changes in bone
mineral density (Koivukangas et al., 2003), 30% increase in bone mineral density
(Madsen et al., 1998), increased calcium content within the callus (Nyman et al., 1993)
and decreased healing callus strength (Tarvainen et al., 1994). Recently, it has been
shown that osteoclasts are a necessary component of efficient endochondral
ossification during fracture repair in mice (Lin and O'Connor, 2016); therefore, it is
possible that clodronate may impair normal bone healing in horses, which calls for
careful consideration when used in a clinical setting.
Therefore, the purpose of this study is to evaluate the effect of clodronate on
bone morphology, bony cells, bone remodeling, and bone healing in young horses.
These evaluations were performed by obtaining bone biopsies of the tuber coxarum
using an established technique (Mitchell et al., 2017), and evaluated through
histomorphometry and microCT. To evaluate bone healing, subsequent biopsies were
taken from the initial biopsy site, which served as a novel bone defect model in the
horse. We hypothesized that clodronate would reduce osteoclast number and function,
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resulting in increased bone volume and increased bone apposition, as well as increased
bone formation after injury.

3.2 Materials and Methods
Study Design
The experimental protocol used for this study was approved by the Louisiana
State University IACUC (Protocol #15-081). Nine clinically healthy Thoroughbred
horses, aged two – four years of age, were used in the study. Horses were obtained
through donation, and did not have a known medical history prior to inclusion within the
herd at the institution’s facility. However, all horses underwent at least a two-week
washout period prior to enrollment in the current study. Horses were randomly assigned
using a coin flip to either a treatment (n=5) or control (n=5) group. Sample sizes were
determined based on donation availability, and all eligible horses were considered.
Additionally, if eligible horses became available during the course of data collection,
they were evaluated and included in order to maximize sample size. A coin flip was
used to randomly assigned horses to a treatment group (i.e., clodronate or saline), and
only the surgeon knew group assignments until subsequent statistical analyses on data
collected were ready to be performed.
Bone biopsies were taken from each horse; a baseline biopsy at Day 0, and a
contralateral (Day 60) and ipsilateral re-biopsy of the initial site (Day 60R) 60 days after
treatment (Figure 3.1). The initial biopsy side was randomly selected via coin flip.
Subsequent to the initial biopsy collection (Day 0), each horse was administered
clodronate (1.8 mg/kg, via IM injection, with the total volume divided into three injection
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locations), or equal volume of 0.9% saline. This dose and route of administration is
standard in the field (FOI, 2014). Prior to the second biopsy collections, the
fluorochrome label oxytetracycline (Vetrimycin 100, VetOne, Boise, ID, USA) was
administered at Day 47 and Day 57 to detect bone remodeling parameters. At Day 60,
two additional biopsies were collected using the same procedure. Analyses of all
biopsies included microCT and histomorphometry evaluations for changes in bone
morphology, remodeling rates, and bone healing.

Figure 3.1 Clodronate study design schematic of time line, outlining biopsy collection
and treatment administration. Abbreviations: Contra., Contralateral; Ipsi., Ipsilateral.
Study Horses
Thoroughbred horses were included for use in the study if they were clinically
healthy and free from apparent musculoskeletal disease, determined through a physical
examination, and were aged 3 to 4 years old (mean weight (± SD): 431.9 ± 52.4).
Horses were housed individually in stalls following surgeries, and were returned to their
respective group pastures after 24-48 hours post-operation, with free choice hay and
water and grain twice daily.
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Surgical Procedure & Treatment
The surgical methods utilized in this study have been previously published in detail
(Mitchell et al., 2017). Briefly, surgeries were performed while horses were restrained in
stocked and sedated with intravenous (IV) xylazine (Xylamed, Bimeda, Cambridge, ON,
Canada) (0.35 to 0.5 mg/kg). A 10 cm by 10 cm square was centered over the palpable
area of the tuber coxarum and was aseptically prepared. Local anesthetic (i.e.,
Lidocaine 2%, VetOne, Boise, ID, USA) was injected subcutaneously superficially down
to the tuber coxarum periosteum, and horses were further sedated with detomidine
hydrochloride (Dormosedan, Zoetis, Kalamazoo, MI, USA) (3 to 5 mg IV) and
butorphanol tartrate (Torbugesic, Fort Dodge, New York, NY, USA) (3 to 5 mg IV)). A
vertical incision was made over the tuber coxarum and was dissected to expose the
cranial, caudal, deep and proximal margins. An oscillating saw was used to cut the
proximal portion of the tuber coxarum, with constant saline lavage to limit thermal
damage. After biopsy removal, the site was lavaged, and sutured closed (Mitchell et al.,
2017). Flunixin meglumine (Prevail, Bimeda, Cambridge, ON, Canada) (1.1 mg/kg IV)
was administered as an additional analgesic and the treatment (either clodronate or
saline) was administered IM.
Following the initial biopsy, horses were stalled for 24-48 hours and monitored for
signs of pain (Doherty and Valverde, 2006). Horses were returned to their group
pastures and monitored daily for complications or lameness until sutures were removed
14 days later. At Day 47 and 57 post biopsy, the bone fluorescent label oxytetracycline
(25 mg/kg) was administered slowly IV. Sixty days after the initial biopsy, two additional
biopsies were collected; the contralateral side (Day 60 biopsy) and a re-biopsy of the
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initial biopsy side (Day 60R biopsy) to evaluate bone healing. Biopsies were obtained
using the same surgical methods as described above. However, careful consideration
was made when placing the oscillating saw for the re-biopsy to ensure an adequatelysized biopsy of the tuber coxarum was obtained without cutting into the pelvis. Surgical
aftercare was identical.

MicroCT
Following biopsy collection, soft tissue was removed from tuber coxae samples,
and biopsies were fixed in 10% non-buffered formalin for 7 days. After fixation, biopsies
were stored in 70% ethanol at 20˚C. For microCT (Scanco model 40, Scanco Medical
AG, Basserdorf, Switzerland) evaluation, biopsies were placed in scanning holders with
70% ethanol, and scanned at 55kV, 0.3-second integration time, with a 30 µm voxel
size in plane and a 30 µm slice thickness. Trabecular bone was selected as the region
of interest, and the proper segmentation threshold was determined and used throughout
for all samples. Trabecular bone was evaluated for bone volume (BV), total volume
(TV), BV/TV, tissue mineral density, trabecular number (Tb.N), trabecular thickness
(Tb.Th), trabecular spacing (Tb.Sp), connectivity density (Con.D), and structural model
index (SMI) based on established procedures and nomenclature (Bouxsein et al., 2010).

Histology
After microCT evaluation, biopsies were prepared for histology as previously
published (Mitchell et al., 2017). Day 0 and Day 60R biopsies were prepared for
decalcified histology, and Day 60 biopsies were prepared for undecalcified histology so
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visualization of fluorochrome labels was possible. Overall, histological preparation of
biopsies differed slightly due to preparation technique required and the necessary size
of the histologic slides. However, careful considerations were made to ensure sections
of each biopsy were taken from the same location and plane of section. Day 0 and Day
60R biopsies were decalcified with 10% ethylenediaminetetraacetic acid (EDTA) and
prepared for routine paraffin embedding. Day 0 and Day 60R biopsies were split in half
and embedded separately, resulting in 6 – 8, 4 µm thick sections per biopsy, and were
stained with hematoxylin and eosin (H&E). Day 60 biopsies were prepared intact for
routine undecalcified histology, producing two, 45-60 µm thick sections. One section
was stained with Stevenel’s Blue and Van Gieson’s picro fusion to evaluate bony cells
and bone morphology via static histomorphometry, and the other section was left
unstained for evaluation of bone remodeling via dynamic histomorphometry.
Histomorphometry evaluations were performed using standard software
(Osteomeasure© Bone Histomorphometry System, Osteometrics, Inc., Decatur, GA,
USA) following standard procedures and nomenclature (Dempster et al., 2013). Static
histomorphometry parameters included direct measurements of: BV, marrow volume
(Ma.V), bone surface (Crook et al.), eroded surface (ES), osteoblast surface (Ob.S),
osteoblast number (Ob.N), osteoclast number (Oc.N), and osteoclast surface (Oc.S).
Indirect static histomorphometry measurements included: Tb.N, Tb.Th, Tb.Sp, and the
direct measurements list above standardized to respective areas and volumes. Dynamic
histomorphometry parameters included mineralizing surface per BS (MS/BS), mineral
apposition rate (MAR) and the bone formation rate per BS (BFR/BS).
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Statistics
To evaluate the effect of clodronate, microCT and histomorphometry data were
analyzed using independent analyses between treatment groups, as well as dependent
analyses between biopsies (Figure 3.2). Prior to statistical comparisons, data were
tested for normality using the Shapiro-Wilk test. Depending on normality, either
parametric or non-parametric analyses were used for each parameter (i.e., paired
Student’s t-test, related samples Wilcoxon signed rank test, independent Student’s t-test
or independent samples Mann-Whitney U test). A related-sample test was used to
evaluate changes from Day 0 biopsy to Day 60 biopsy, or Day 0 biopsy to Day 60R,
within the control or treated horses. An unrelated-sample test was performed to
evaluate difference between treated and control horses within Day 60 biopsy or Day
60R biopsy. Statistical analyses were performed using commercially-available software
(SPSS, version 24, IBM Corporation, Armonk, New York, USA), and p-values of <0.05
were considered significant. If a parameter was significant but not normalized to
respective biopsy size measurements, it was not reported (e.g., BV versus BV/TV). Due
to the aforementioned issues with obtaining microCT data from two Day 0 biopsies, all
data from those horses were excluded from dependent analyses.

3.3 Results
Surgical Technique
One horse (control group) was lost during the study and was euthanized due to
reasons unrelated to the study, and was therefore not included in subsequent analyses.
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Figure 3.2 Schematic of statistical comparisons for microCT and histomorphometry
data.
Horses received between 660 – 800 mg (mean ± SD, 783.0 ± 81.8 mg) of clodronate
based on weight. All surgeries were successful in obtaining adequately-sized bone
biopsies during each attempt, with no horses showing post-surgical lameness or
complications. Day 0, Day 60 and Day 60R biopsies had a mean (± SD) TV of 1731 ±
78, 1467 ± 453 and 1080 ± 646 mm3, respectively.

Bone Morphology
Due to technical difficulties, microCT analyses were only performed on three of
the five Day 0 biopsies from the treated group. When comparing data from treated
horses to control horses within the Day 60 biopsy, there was no significant effect of
clodronate treatment on any of the 19 total bone morphology parameters as evaluated
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by microCT (Figure 3.3). Similarly, there were no significant changes in bone
morphology parameters between Day 0 and Day 60 biopsies within treated horses, or
within control horses, as evaluated by MicroCT.
When comparing Day 0 biopsy to Day 60 biopsy within the control horses,
several histomorphological parameters were significantly different: Day 0 biopsy was
significantly greater than Day 60 biopsy in BV/TV (p=0.02) (Figure 3.3), and Oc.S/BS
(p=0.04), and Day 60 biopsy was greater than Day 0 biopsy in Tb.Sp (p=0.01) and
Ma.V/TV (p=0.02). When making the same comparison within treated horses, Day 0
biopsy was greater than Day 60 biopsy in Void Surface/BS (p=0.049), and Ob.N/TA
(p=0.03) (Table 1), and Day 60 biopsy was greater than Day 0 biopsy in
Ob.N/Ob.Perimeter (p=0.02). Overall, changes from Day 0 to Day 60 within control
horses affected three out of 20 bone morphology parameters, and one out of 10 bone
resorption parameters. Changes from Day 0 to Day 60 within treated horses showed
differences in one out of 20 bone morphology parameters, and two out of 20 bone
formation parameters.

Bone Remodeling
After 60 days, clodronate did not significantly alter any of the 14 bone remodeling
parameters evaluated via dynamic histomorphometry (Figure 3.3).

Bone Healing
When comparing treated horses to control horses within the Day 60R biopsy,
there was no significant effect of clodronate on any of the 19 bone morphology
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parameters, as evaluated by microCT. Comparing Day 0 biopsy to Day 60R biopsy
within control horses and then again within treated horses, there were no significant
differences in any of the 19 bone morphology parameters evaluated via microCT.
When comparing Day 0 to Day 60R within control horses, the Day 60R biopsy
had significantly higher ES/BS (p=0.049). Comparing Day 0 biopsy to Day 60R biopsy
within treated horses, the same effect in ES/BS (p=0.03) was observed. Comparing
treated horses to control horses within the Day 60R biopsy, treated horses had
significantly higher BS/TV (p=0.02) and Tb.N (p=0.02), and significantly less Ob.S/BS
(p=0.04). Overall, two out of 20 bone morphology parameters and one out of 20 bone
formation parameters were significantly affected.

3.4 Discussion
This study details the effect of a single dose of clodronate on bone cells,
morphology, remodeling, and healing in 5 healthy, young Thoroughbred horses. This is
the first study that has evaluated bony changes due to clodronate in the horse, despite
its prolific use in veterinary clinics. Additionally, clodronate’s effect in horses under 4
years of age has not been determined. Overall, the data presented here demonstrates
that overall there were no effects of clodronate after 60 days on bone morphology or
remodeling when compared to the control group and when compared to baseline
biopsies from the same horse, using the prescribed dose and route of administration.
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Figure 3.3 Summary data (mean ± SD) of bone structure and remodeling parameters from Day 0, Day 60 and Day 60R
biopsies for microCT, static histomorphometry and dynamic histomorphometry analyses in control (n=4) and treated (n=5)
horses. Abbreviations: BV/TV, bone volume fraction (bone volume/total volume); Tb.Th, trabecular thickness; Tb.N
trabecular number; Con.D, connectivity density; Ob.N/TA, number of osteoblasts per tissue area; Oc.N/TA, number of
osteoclasts per tissue area; sL.S/BS, single label surface per bone surface; dL.S/BS, double label surface per bone
surface; MAR, mineral apposition rate; BFR/BV, rate of bone formation (bone formation rate per unit of bone volume).
a,b
Significant (P ≤ 0.05) difference between values with the same letter superscript. P-value results from paired Student’s
t-test. * Sample size for treated Day 0 biopsies contains 3 horses for microCT analysis.
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One limitation to the current study is a lack of evaluation in a model of
pathological bone remodeling, and a lack of clinical evaluations on lameness. However,
a barrier to the field is that there is currently no data regarding whether clodronate does
or does not affect bone remodeling in the horse at the doses administered. It is well
known that bisphosphonates are powerful modifiers of the bone remodeling process,
including in normal bone (Mashiba et al., 2005). Therefore, it is hypothesized that if
there were a systemic effect of clodronate administration in the horse at the routine
clinical dose administered, it would have been detected in the current study. As outlined
above, treatment success in the previous study (FOI, 2014) may have been based on
clodronate’s pain-minimizing properties, and not due to changes in bone remodeling.
This would explain the treatment success demonstrated in that clinical trial (FOI, 2014),
but support the lack of bony changes shown in this study. However, a novel aspect of
the current study is the evaluation of the effect of clodronate on bone healing secondary
to a bone defect (i.e., the biopsy). Bone healing during clodronate use has been
evaluated in rats (Madsen et al., 1998, Koivukangas et al., 2003), with no reports of
adverse effects on bone remodeling (Koivukangas et al., 2003), but conflicting results
on bone callus formation during fracture repair (Nyman et al., 1993, Nyman et al., 1996,
Madsen et al., 1998). In this study, although not specifically evaluating fracture repair,
we too found minimal effects on bone healing after injury.
The biopsy location, the tuber coxarum, used in the current study may not be
representative of normal bone remodeling throughout the equine skeleton. However,
previous work has shown that tiludronate, a bisphosphonate similar in structure and
pharmacokinetics to clodronate (Lin, 1996), has been shown to accumulate in the bone
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at highest concentrations within tuber coxae (Delguste et al., 2011). Thusly, while no
such data exists for clodronate, given the similarities between tiludronate and
clodronate, the tuber coxae are assumed to accumulate high concentrations. Similarly,
the tuber coxae do not experience the same specific biomechanics experienced in the
equine distal limb, specifically the navicular bone. It is possible that exercise may
influence the effect of bisphosphonates on bone remodeling. Using the tuber coxae is a
potential limitation in regards to conclusions about weight-bearing bones, given that
clodronate is indicated for treatment of abnormal bone remodeling that primarily occurs
in the distal limb in horses. However, bisphosphonates have been repeatedly shown to
have systemic effects on bone (Drake and Cremers, 2010), especially trabecular bone
(Pataki et al., 1997), so it can be reasonably argued that any changes that would occur
secondary to treatment with clodronate would be identified in the selected biopsy
location. Similarly, the pelvis has been identified as a location that can accurately
represent changes found in weight bearing regions of the skeleton, such as the
vertebrae (Mashiba et al., 2005).
While some significant differences in bone morphology were identified
histologically, these changes were not confirmed via microCT, which represents a
comprehensive evaluation of bone structure in three dimensions, as compared to twodimensional histological assessments. While histomorphometry is excellent tool for cell
and remodeling analyses of a slice of the total biopsy, microCT accounts for the entire
biopsy volume. Therefore, despite small differences reported, the authors conclude that
overall effects of clodronate on bone morphology and remodeling were insignificant in
young horses after 60 days. Overall, there were small differences noted between
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clodronate and saline comparisons. However, these differences were minor, and do not
make biological sense as a stand-alone parameter in the broad overview of bone
formation and resorption. It is possible that the changes seen in the control group are
normal bony changes for this time frame, and clodronate preventing these changes
from occurring in the treated group. However, as the changes reported are not
consistent with overall changes expected. The low sample size may have limited the
overall power of our analyses, but given the known efficacy of clodronate in other
species on altering bone resorption (Minaire et al., 1986), even a small difference, if
present, was expected to be observed. The 60 day duration of this study is short;
however this duration has been used in other studies examining bone remodeling
(Rohde et al., 2000) and is associated with clinical improvement of lameness in the
majority of horses treated with either clodronate or tiludronate (Denoix et al., 2003,
Gough et al., 2010, FOI, 2014). Clinical improvement in lameness may not be related to
changes in bone morphology or remodeling, but without investigating the effects in
normal horses, pathologic changes or responses following therapy will be harder to
identify. Additionally, our study utilized both internal controls and a separate control
group, and found no additional differences in any parameter using these comparisons.
However, future evaluations should utilize a larger sample size to increase power to
determine if clodronate has minimal effect on bone remodeling.
In conclusion, we found that clodronate has no effect on bone morphology, as
evaluated via microCT, and no effect on bone remodeling after 60 days in young
horses. There were minimal effects found via static histomorphology; however, these
results are insignificant in the absence of microCT data and other normalized
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parameters. Additionally, we determined that clodronate does not negatively affect bone
healing in the presence of a bone injury, in this skeletal location, after 60 days.
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CHAPTER 4.
ANATOMICAL VARIATION OF THE TARSUS IN COMMON INBRED
MOUSE STRAINS2
4.1 Introduction
Rodent models are widely used in orthopedic and biomechanical research, which
rely upon accurate knowledge of the anatomy of the hind limb (Gillis and Biewener,
2001, Settle et al., 2003, Glasson et al., 2007, Rose et al., 2013, Banzrai et al., 2016).
Their small size, fully sequenced genome (Corsortium et al., 2002, Adams et al., 2015)
and short lifespan make them a common candidate for translational studies related to
human disease. Therefore, detailed and accurate anatomical descriptions are extremely
important for any translational research that involves the musculoskeletal system of
rodents. Prior to the advent of novel technologies that allow advanced imaging of
various tissues and organ systems, scientists relied on artistic interpretations of
anatomy (Cook, 1965, Rugh, 1968, Popesko et al., 1992) for references. These
drawings are still used today as anatomical references for research and education.
These references describe the tarsal anatomy of mice (Mus muscus) as having eight
bones, including tarsal bones I (os tarsale I), II (os tarsale II), III (os tarsale III) and IV
(os tarsale IV), medial tibial (tibiale mediale), central (os tarsi centrale), calcaneus and
talus (Cook, 1965, Rugh, 1968). The anatomy of the murine tarsus, as described by
Cook (Cook, 1965) and Rugh (Rugh, 1968), is identical to the anatomy found in the rat
(Popesko et al., 1992).

2

This chapter previously appeared as Richbourg, H. A. et al. Anatomical Variation of
the Tarsus in Common Inbred Mouse Strains. Anat Rec (2016) DOI: 10.1002/ar.23493.
Reprinted by permission of John Wiley and Sons via RightsLink.
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While useful, these conventional references do not depict three-dimensional (3D)
relationships between anatomical structures. Published anatomical descriptions have
expanded to include high resolution, 3D images and models of anatomy derived from
computed tomography (Yakatan et al., 1982) scans from several species. The skeletal
anatomy of a C57Bl/6 (Black6) laboratory mouse has been characterized in extensive
detail by utilizing microCT (Bab et al., 2007), and conflicting data describing murine
tarsal anatomy has been observed between the established anatomical illustrations
(Cook, 1965, Rugh, 1968) and the more recent text (Bab et al., 2007) that uses microCT
to describe murine skeletal anatomy. When examining the tarsus in high-resolution
microCT scans of a 10-week-old male Black6 laboratory mouse (Bab et al., 2007), the
central tarsal bone and tarsal bone III are fused; however, this fused bone is labeled as
the navicular bone (i.e. central tarsal bone) with no discussion on the absence of the
tarsal bone III. Additionally, Duce et al. (Duce et al., 2010) reported difficulty in
determining the interface between the central and tarsal bone III in Black6 mice during
digital segmentation of micro-magnetic resonance imaging (MRI) data.
Normal variation in tarsal bone anatomy has been documented in several other
species, both domestic and exotic (Shubin et al., 1995, Dyce et al., 2010). Although
normal variation in ossification patterns within rodents has been documented (Wilson et
al., 2010), normal variations in tarsal anatomy within mice remain undocumented. This
lack of knowledge impacts studies that have identified abnormalities of the tarsus in
mice afflicted with mutations affecting the expression of growth and differentiation
factors (GDF) 5 and 6 (Grüneberg and Lee, 1973, Storm et al., 1994, Settle et al., 2003,
Tassabehji et al., 2008). One of these mutations is characterized as brachypodism, a
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disease that is caused by a recessive gene mutation that affects the appendicular
skeleton, resulting in shortened long bones and fusion of bones within the tarsus and
carpus (Grüneberg and Lee, 1973, Storm et al., 1994, Seemann et al., 2005). In these
studies, the fusion of tarsal bone III and the central tarsal bone is represented as an
abnormal consequence of gene mutations in commonly used inbred laboratory mouse
strains. Due to conflicting information between these studies and anatomical references,
documenting the detailed anatomy of the tarsal anatomy in mice is important for future
work involving the skeletal structures in this region. Therefore, the purpose of the
current study is to characterize the normal anatomy of the tarsus and to clarify the
presence and number of bones within this region in normal laboratory mice, evaluating
both young and mature individuals of multiple lineages. To determine the phylogenetic
extent of the potentially derived tarsal anatomy observed in laboratory mice, they are
compared with other closely related murines by evaluating the rat (Rattus norvegicus);
and a member of Cricetidae as the outgroup, the more distantly related white-footed
mouse (Peromyscus leucopus) (Blanga-Kanfi et al., 2009).

4.2 Materials and Methods
Study Design
Left hind limbs from 17 laboratory mice, 2 white-footed mice and 5 rats were
collected. To accurately determine variation in hind limb bony anatomy, tarsi from these
specimens

were

analyzed

via

high-resolution

microCT.

Three-dimensional

reconstructions of the tarsal bone anatomy were then made for comparisons as outlined
below. In addition, decalcified histology of the tarsus from the hind limb of one Black6
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laboratory mouse and one BalbC laboratory mouse was analyzed to confirm tarsal bone
fusion.

Specimens
All specimens in this study were collected post-mortem as discarded tissues
under approved IACUC protocols, and were not included in concurrent studies involving
musculoskeletal disease before euthanasia. Details regarding the specimens utilized in
the study are outlined in Figure 4.1. In short, two laboratory strains of mice (M. muscus;
Black6, n=15; and BalbC, n=2), white-footed mice (P. leucopus, n=2) and laboratory
rats (R. norvegicus, Sprague Dawley, n=5) were evaluated. Within the Black6 inbred
laboratory mice, hind limbs from mice of various ages were included: 24 weeks (n=7),
16 weeks (n=3), 11 weeks (n=3), 8 weeks (n=1) and 3.5 weeks (n=1). The left hind limb
from each specimen was disarticulated at the coxofemoral joint and fixed in 10%
neutral-buffered formalin prior to analysis.

Micro-computed tomography and 3D reconstruction
Samples were scanned (Scanco Model 40, Scanco Medical AG, Basserdorf,
Switzerland) in 70% ethanol at 55 kV, 145 μA with various isotropic voxel resolutions
(outlined in Table 4.1) due to limb size. The region of interest (Bouxsein et al., 2010) for
microCT scanning included the region between the distal tibia to the proximal
metatarsal bones. Each scan was exported as a set of DICOM files and imported to the
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Figure 4.1 Characteristics for study samples utilized, including common name, species
name, specific strain (if applicable), age (if known), sex, the number of samples per
category and the microCT scanning resolution. Exact ages are not known for animals
obtained from the field, so maturation was deduced based on closure of physes within
the hind limb. For age reference, sexual maturity of the mouse and rat is estimated to
be as early as 4 to 5 weeks.
imaging software Amira version 6.0.1 (FEI Software, Hillsboro, OR, USA). Anatomical
features were segmented by hand, using a Wacom Intuos Pro large tablet (Wacom
Technology

Corp.,

Vancouver,

WA,

USA).

Standard

veterinary

nomenclature was utilized throughout the study (Nomenclature, 2012).

81

anatomical

Histology
Following microCT scanning, a representative hind limb from one Black6 and
BalbC laboratory mouse were prepared for routine decalcified histology. The hind limbs
were decalcified in 10% ethylenediaminetetraacetic acid (EDTA) for two weeks,
processed, embedded intact into paraffin and serially sectioned in the sagittal plane.
Four to five representative sections were selected through the central tarsal region,
ensuring inclusion of the central tarsal bone and tarsal bone III, and stained with
hematoxylin & eosin (H&E). Sections were evaluated for presence of joint space,
hyaline cartilage and/or subchondral bone.

4.3 Results
MicroCT and Digital Models
The laboratory mouse tarsus has seven individual tarsal bones: the calcaneus,
talus, fused central and tarsal bone III, medial tibial bone and tarsal bones I, II, and IV
(Figure 4.2). The tibia and fibula articulate distally with the talus, and the tarsocrural joint
incorporates the distal tibia and fibula, talus and calcaneus. The proximal row of tarsal
bones includes the medial tibial bone, talus and calcaneus. The talus articulates with
the calcaneus caudally, medial tibial bone medially and the fused central and tarsal
bone III distally. The middle row of tarsal bones is composed of the proximal portion of
tarsal bone I, proximal portion of the fused central and tarsal bone III and tarsal bone IV
(medial to lateral), and the distal row consists of the distal portion of tarsal bone I, tarsal
bone II, distal portion of the fused central and tarsal bone III and the distal portion of
tarsal bone IV (medial to lateral). The metatarsals are distal to the tarsal bones,

82

consisting of (medial to lateral) metatarsals I, II, III, IV, and V. Each metatarsal bone
articulates with the corresponding tarsal bone (i.e., metatarsal I articulates with tarsal
bone I), with the exception of metatarsal V, which articulates with the distal portion of
tarsal IV. Metatarsal V protrudes the furthest proximally of the metatarsals.
In contrast, the rat and white-footed mouse have a separate central tarsal bone
and tarsal bone III (Figure 4.2), consisting of 8 separate tarsal bones (full pes shown in
Figure 4.3). Two-dimensional slices from microCT scans confirm fusion of the central
and tarsal bone III in both strains of laboratory mice, and separation in the rat (Figure
4.4). In this particular white-footed mouse specimen, metaphyseal physes were not
ossified in the proximal and distal tibia, proximal and distal fibula, proximal metatarsal I
and metatarsal V; in addition, the apophysis that gives rise to the tuber calcanei was not
ossified, indicating that this specimen was skeletally immature. Similar to the whitefooted mouse, metaphyseal physes were not ossified in the tibia, fibula and metatarsal I
in the 3-week- old Black6, and the fibula in the 8-week-old Black6. Similarly, the
apophysis that gives rise to the tuber calcanei was not ossified in the 3- and 8-week-old
specimens. Comparative tarsal anatomy of the laboratory mouse, rat and white-footed
mouse are shown in Figure 4.5.

Histology
Sagittal sections of the tarsus in both the adult Black6 and BalbC mice show a
single, fused central and tarsal bone III (Figure 4.6). In both samples, a horizontal band
of healthy hyaline cartilage was present near the approximated fusion site, but is
surrounded by healthy and intact trabecular bone.
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Figure 4.2 Representative 3D reconstructions of the left tarsus (cranial view) of A) adult
Black6 mouse, B) adult BalbC mouse, C) 8 week old Black6 mouse, D) 3.5 week old
Black6 mouse, E) rat, and F) white-footed mouse. Abbreviations: Cal, calcaneus; Cen,
central tarsal bone; Cen & T3, fused central and tarsal bone III; Fib, fibula; Med T,
medial tibial bone; Met, metatarsals; Ses, sesamoid; Tal, talus; Tib, tibia; T1, tarsal
bone I; T2, tarsal bone II; T3, tarsal bone III; T4, tarsal bone IV. Scale bar = 0.5 mm.
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Figure 4.3 Three-dimensional reconstructions of the left pes of the white-footed mouse
(P. leucopus) in medial, cranial and lateral view from left to right. Abbreviations: Cal,
calcaneus; Cen, central tarsal bone; Fib, fibula; Med T, medial tibial bone; Met1,
metatarsal I; Met5, metatarsal IV; Ses, sesamoid; Tal, talus; Tib, tibia; T1, tarsal bone I;
T2, tarsal bone II; T3, tarsal bone III; T4, tarsal bone IV. Scale bar = 2.5 mm.
4.4 Discussion
In this study, we determined that the fusion of the central and tarsal bone III is present
in both strains of laboratory mice examined. Considering that the fusion was present in
all individuals of varying ages (n=17), we conclude this to be a ubiquitous tarsal
characteristic in laboratory mice. In addition to microCT evaluations, histology further
confirmed this fusion. Our findings contradict the majority of previously published data
(Cook, 1965, Rugh, 1968, Popesko et al., 1992) but support the recent images
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Figure 4.4 Representative sagittal (A, C, E) and transverse (B, D, F) slices from
microCT scans showing the central (purple) and tarsal bone III (blue) in the adult Black6
mouse (A, B), adult BalbC mouse (C, D) and rat (E, F). Abbreviations: Tal, talus; Cal,
calcaneus; Cen & T3, fused central and tarsal bone III; Cen, central; T1, tarsal bone I;
T2, tarsal bone II; T3, tarsal bone III; T4, tarsal bone IV; Met2, metatarsal II; Met5,
metatarsal V. Scale bar = 0.5 mm.
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Figure 4.5 Three-dimensional reconstructions for comparative anatomy of the left pes of
the A) adult BalbC mouse (M. musculus), B) rat (R. norvegicus), and C) white-footed
mouse (P. leucopus) in medial, cranial and lateral view from left to right. Abbreviations:
Tib, tibia and fibula; Tal, talus; Ses, sesamoid; Cal, calcaneus; Med T, medial tibial; Cen
& T3, fused central and tarsal bone III; Cen, central; T1, tarsal bone I; T2, tarsal bone II;
T3, tarsal bone III; T4, tarsal bone IV; Met, metatarsals. Scale bar = A) 0.5 mm, B) 2.5
mm, C) 1 mm.
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Figure 4.6 Decalcified H&E stained histologic sagittal sections from a representative
adult BalbC mouse (A & B) and adult Black6 mouse (C & D). Arrowheads designate
hyaline cartilage within the fused central and tarsal bone III. Scale bars = 500 μm (A &
C) and 100 μm (B & D).
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published by Bab et al. (Bab et al., 2007). This study further characterizes these
differences in two strains of mice by comparing the laboratory mouse morphotype to the
closely related rat and the more distant white-footed mouse. Due to the fact that the
observed tarsal fusion was not present in the rat, we believe this fusion to be a recent
development due to extensive selective breeding of laboratory mice, potentially
expediting evolutionary changes. In addition, histological evaluations showed the
presence of hyaline cartilage in both laboratory strains, demonstrating that the central
bone and tarsal bone III were likely, at one point, two separate bones. The presence of
cartilage could indicate that either the bone has completely fused and this is the
remnant of the joint space, or the bone has only partially fused, and the presence of the
cartilage surrounded within bone is simply an orientation limitation of a two-dimensional
view. It is possible that this fusion could have occurred during normal postnatal growth
and development, as studies evaluating bone development show these bones as being
separate in young mice (Storm et al., 1994, Patton and Kaufman, 1995); however, our
findings are somewhat contradictory, as we identified this fusion in mice as young as
three weeks old. One limitation to our study was that only one laboratory mouse at three
weeks of age was analyzed. A potential explanation for these anatomical differences
could be the different laboratory mouse populations. The laboratory mice used in this
study were either purchased from the Jackson Laboratory or bred on site.
Several studies have characterized the fusion of the central and tarsal bone III as
an abnormal finding secondary to mutations associated with brachypodism (Storm et
al., 1994). Storm et al. (Storm et al., 1994) found fusion of the central and tarsal bone III
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in BalbC mice with null mutations in GDF5 during embryonic development. It is thought
that disrupting various members of the bone morphogenic proteins (BMPs) may affect
differentiation and separation of precursor bones within the carpus and tarsus (Storm et
al., 1994). In contrast, our data demonstrate that fusion of the central and tarsal bone III
is likely a normal maturation characteristic, and not a pathological finding as described
(Grüneberg and Lee, 1973, Storm et al., 1994). Furthermore, if this fusion in the tarsal
bones occurred as the result of a genetic mutation within the inbred laboratory mouse
strains, it is possible that this change occurred during the 20-50 years since those
studies were published, meaning that the normal mice included in those studies did
indeed have separated tarsal bones. More recently, Duce et al. (Duce et al., 2010)
reported difficulties distinguishing the boundaries of the central and tarsal bone III using
micro-magnetic resonance imaging of Black6 mice. These difficulties could be explained
by our results. Our findings directly impact these studies, as we have shown that this
fusion is not a lesion secondary to disease, and is in fact a normal occurrence within
two laboratory mouse strains.
The central and tarsal bone III in the white-footed mouse are unfused and remain
two distinctly separate bones. It is possible that fusion could occur in a later phase of
maturation of the white-footed mouse; however, this does not appear to be the case, as
the laboratory mice with a similar epiphyseal plate status show fused tarsal bones. In
addition, tarsal bones ossify with a single center of ossification during development
(Patton and Kaufman, 1995), thus normal postnatal fusion of these two bones is
unlikely. Differences in the white-footed mouse and a laboratory mouse may be due to
differences in locomotion (i.e., semi-saltatorial versus scansorial) or due to their distant
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phylogenetic relationship. In addition, only two white-footed mice were available for
evaluation. Future studies would require further and more comprehensive analyses of
the tarsal anatomy of wild typed mice of various ages for direct comparisons to the
skeletal anatomy of their distant inbred relatives.
The absence of fusion in the closely-related rat shows that this fusion is specific
to the laboratory mouse and is not an ancestral state. The fusion of the central bone
and tarsal bone III is most likely the result of a genetic mutation from human-directed
breeding; however, evaluations of a wild type M. musculus is necessary to determine if
this fusion is only present in laboratory mice or also found in other populations. Although
the mice used in this study are bred as control, wild type mice, they have still been
subjected to inbreeding, and therefore may not reflect the true wild type state of mice.
Herein we were able to successfully show that fusion of the central and tarsal
bone III is a normal characteristic in adults of two strains of inbred laboratory mice
commonly used for orthopedic research, as well as characterize the tarsal anatomy for
the white-footed mouse and rat. Although we guardedly apply this conclusion to all
strains and populations of laboratory mice due to sample size, we believe these findings
should be considered for studies requiring detailed knowledge of tarsal anatomy in
these species. It is possible that there are biomechanical consequences of the fusion of
the central and tarsal bone III; however, the fusion does not span the entire distal
intertarsal joint, and therefore only limits range of motion in the center of the joint. Joint
fusions are common in horses with distal intertarsal osteoarthritis, and after surgical
fusion, horses return to athletic performance without hindrance on range-of-motion in
the tarsus (Dechant et al., 2005). Therefore, although the fusion of the central and tarsal
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bone III may limit the overall movement of the joint, it likely does not have major
consequences on gait. Clarification of the timing of fusion should be evaluated through
the investigation of additional stages, including embryogenesis, as studies evaluating
the effects of GDF 5/6 mutations in tarsal anatomy evaluate developmental anatomy. In
addition, older mice (i.e., >1 year of age) should also be evaluated to determine if the
cartilage and joint space observed disappears, indicating that fusion is actively
occurring later in life.
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CHAPTER 5.
CONCLUDING REMARKS
5.1 Overall Summary of Findings
The use of imaging in veterinary medicine has greatly advanced orthopedic
research for both research and education purposes. This dissertation utilized one of
these advanced imaging techniques, microCT, to analyze bone morphology in two
animal models, answering several relevant questions in veterinary orthopedics: the
effect of two FDA-approved bisphosphonate therapies (i.e. tiludronate and clodronate)
on bone morphology and remodeling in horses, and the presence of tarsal variation in
laboratory mice. In addition, this dissertation describes a novel, non-terminal bone
biopsy method in the horse, providing the largest bone sample when compared to other
methods previously described.
In Chapters 2 and 3, the aforementioned bone biopsy model was utilized to
collect bone samples from the tuber coxarum of young, clinically healthy horses. Bone
samples were analyzed via microCT and histomorphometry to determine the effect of
clodronate and tiludronate on bone structure and remodeling. In addition, the effect of
clodronate on bone healing after a bone defect was analyzed. We determined that
tiludronate and clodronate, administered at the recommended dose, do not have an
effect on bone morphology or bone remodeling after 60 days in young horses. However,
tiludronate and clodronate may have preventing minor bony changes, as seen in the
control group, from occurring in the treated horses. Additionally, clodronate does not
appear to impact bone healing 60 days following creation of a defect.
In Chapter 4, we characterized the bony tarsal anatomy in two common strains of
laboratory mice (i.e., Black6 and BalbC), and compared this anatomy to selected
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outgroups: the closely-related laboratory rat and the distantly related white-footed
mouse. Utilizing microCT and histology, we confirmed that the central and tarsal bone III
were fused in all laboratory mice evaluated. This fusion was not present in the rat or
white-footed mouse. Histological sections showed the presence of hyaline cartilage
surrounded by mature, trabecular bone. We conclude that although the bone is fused in
these mice, a joint remnant remains.

5.2 Significance of Research
Assessment of bone health through bone biopsies in many species, including
horses, is typically accomplished through obtaining a core biopsy from the sternebrae,
ribs, third metacarpal bone, fourth tarsal bone and tuber coxae (Misheff et al., 1992,
Steiger et al., 1999, Désévaux et al., 2000, Delguste et al., 2011), which has been
shown to have poor trabecular bone for histological evaluation (Steiger et al., 1999).
The biopsy method described in this dissertation produced biopsies almost 9 times
larger than previously described biopsy volumes from other locations (Savage et al.,
1991, Misheff et al., 1992, Steiger et al., 1999), with no associated morbidity or postsurgical lameness. Additionally, we showed that the biopsy model proposed in the
current studies allows one to obtain sequential biopsies, permitting evaluation of bone
across several time points.
Currently, tiludronate and clodronate are used extensively in the veterinary
clinical setting to treat abnormal bone remodeling diseases (Denoix et al., 2003),
including to young horses (Carpenter, 2012), which are known to undergo more rapid
bone remodeling than skeletally-mature adults (Goyal et al., 1981). Despite the wide
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use of clodronate in the clinical setting, and it’s known systemic impact on the entire
skeleton, there has been little to no research evaluating the effect of these drugs on
normal bone remodeling in horses. Additionally, the effect of these drugs in young
horses, who may be skeletally immature and undergoing increased bone remodeling
and growth secondary to normal development, has not been evaluated. Our research
shows that these drugs have minimal to no short-term effect on normal bone structure
and remodeling in young horses. Additionally, we showed that in the presence of a bone
defect, clodronate does not negatively affect normal bone remodeling after 60 days.
Rodent models are used for a variety of orthopedic research applications,
including characterization of pathologic bony changes secondary to disease (Eulderink
et al., 1998, Ford-Hutchinson et al., 2003, Goupil et al., 2016). Therefore, correct
representations of normal bony anatomy are crucial in determining normal
characteristics versus pathologic characteristics. Additionally, surgical procedures are
guided by current knowledge of anatomy. Standard references for mouse anatomy
show the mouse tarsus containing 8 individual bones (Cook, 1965), while a recent atlas
of the mouse, utilizing microCT, demonstrated a fusion between two bones, and
consisted of 7 individual bones (Bab et al., 2007). However, this atlas did not describe
the fusion nor characterize it in relation to previous published anatomical descriptions of
the tarsal region. Therefore, we were able to show that this fusion is present in two
strains of wild-type laboratory mice. This fusion needs to be considered when studying
diseases of the tarsus, or for surgical procedures involving the tarsus of mice.
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5.3 Future Directions
The results presented in this dissertation show that tiludronate and clodronate do
not affect bone structure and remodeling after 60 days. The next milestone of this
project is to determine longer term effects of tiludronate and clodronate on bone, as well
as increase sample size to determine if lesser effects exist. Additionally, due to their
minimal effect shown in this study, the effect of tiludronate and clodronate on diseased
bone in horses, specifically associated with navicular disease, needs to be evaluated as
well, to determine the efficacy of these BPs.
We showed that fusion of the central and tarsal bone III is a normal characteristic
in two strains of wild-type laboratory mice. Therefore, the next goal of this project is to
evaluate additional individuals to increase sample size of the BalbC strain, as well as
evaluate additional wild-type strains. Moreover, evaluating individuals from various
mouse colony populations will help elucidate the extent of the fusion into all laboratory
mice populations. Further evaluation of the anatomical extent of the fusion is also
necessary, to determine if surrounding musculature and neurovasculature are affected.
Finally, once affected mouse strains are known, determining genetic differences
between mice with a fused bone versus mice without will facilitate researchers in
determining the cause of the fusion, and possible interactions with future studies
evaluating genetic manipulations or pathology.
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